Cylon Pharmaceuticals: Subsidiary Receives Approval for Pregabalin Listing Application
() Announcement: Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary, has recently received the approval of Pregabalin’s "Notice of Application for Marketing of Chemical APIs" issued by the State Drug Administration.
Cylon Pharmaceutical: Subsidiary Receives Approval of Pregabalin Chemical API Listing Application
On March 7, Cylon Pharmaceutical announced that its subsidiary had received approval for the listing of Pregabalin chemical raw materials.
Cylon Pharmaceutical: Subsidiary Received Notification of Approval for the Listing Application of Pregabalin, a Chemical API
Sailon Pharmaceutical announced on the evening of March 7 that Hunan Sailon Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has recently obtained the approval of pregabalin "Chemical API Marketing Application Approval Notice" issued by the State Food and Drug Administration. The main indications of pregabalin are: for the treatment of post-herpetic neuralgia and fibromyalgia.
Cylon Pharmaceutical: Subsidiary chemical raw material drug "pregabalin" was approved for listing
Sailong Pharmaceutical announced that Hunan Sailong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, has recently obtained the "Notice of Approval for the Marketing of Chemical API" approved by the State Drug Administration. It is reported that the main indications of pregabalin are: for the treatment of post-herpetic neuralgia and fibromyalgia.
Lisheng Pharmaceutical: Ticagrelor API passed the marketing application
() Announcement: The company has received the "Notice of Approval of Application for Listing of Chemical APIs" issued by the State Drug Administration for ticagrelor APIs, and the variety has passed the application for listing of chemical APIs.
Garden Bio completed the repurchase of 1.69% of the shares, costing 100 million yuan
() announcement, as of March 6, 2024, the company through the share repurchase special securities account to the centralized auction transaction to repurchase the company’s shares 9.3072 million shares, accounting for 1.69% of the company’s current total share capital, the minimum transaction price is 10.09 yuan/share, the highest transaction price is 11.83 yuan/share, the total transaction amount is RMB 100 million yuan (including transaction costs). The company’s repurchase has been completed, the actual repurchase time range is September 14, 2023 to March 6, 2024.
The shareholders’ meeting will be held on March 22 to consider the company’s proposal to apply for a project loan from the bank as collateral for its own assets
Rifeng shares announced that the third extraordinary general meeting of shareholders will be held on March 22, 2024, and the online voting will be held on the same day. The equity registration date is March 15, and investors who hold Rifeng shares after the market closes on that day can participate in the voting.
Meeting place: Conference room on the first floor of Guangfeng Industrial Park Company, West District, Zhongshan City.
The shareholders’ meeting audited a total of one proposal, as follows:
1. Proposal on the company applying for a project loan from the bank with its own assets as collateral.
ST plans to sell a 17% stake in CCCC New Energy and optimize its investment structure
() Announcement, the company plans to transfer the 17% equity of Jiangsu CCCC New Energy Technology Co., Ltd. (referred to as "CCCC New Energy") held by its wholly-owned subsidiary Nanjing Keshu Technology Co., Ltd. (referred to as "Nanjing Keshu") to Lu Yicheng at a price of 40 million yuan. After the transfer is completed, Nanjing Keshu will no longer hold the equity of CCCC New Energy.
The announcement said that the company’s current main business is cross-border e-commerce export, and its long-term development strategy in the future lies in focusing on strengthening core business capabilities and further strengthening and refining the main business of cross-border e-commerce. In order to further protect the company’s ROI, optimize the company’s investment structure, and improve the asset quality and profitability of listed companies, the company has decided to transfer the equity of CCCC New Energy.
Jujie Microfiber: The controlling shareholder intends to increase its holdings by 15 million yuan – 30 million yuan
() Announcement that the controlling shareholder Suzhou Jujie Investment Co., Ltd. intends to increase its holdings by not less than 15 million yuan and not more than 30 million yuan.
Jujie Microfiber: The controlling shareholder of the company plans to increase its holdings by 15 million yuan – 30 million yuan
On March 7, Jujie Microfiber announced that the company’s controlling shareholders plan to increase their holdings by 15 million yuan – 30 million yuan.
Jujie Microfiber’s controlling shareholder plans to spend 15 million yuan to 30 million yuan to increase shares
Jujie Microfiber announced that the controlling shareholder of the company, Suzhou Jujie Investment Co., Ltd. (referred to as "Jujie Investment", "the main body of the increase") plans to increase its holdings of the company’s shares within the next 6 months from the date of this announcement through the means allowed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.), with a total amount of not less than RMB 15 million yuan and not more than RMB 30 million yuan.
Dong Chunhong, supervisor of Tuoxin Pharmaceutical, has reduced his holdings by 1,000 shares
() announcement, the company received the "notice letter on the expiration of the implementation time of the share reduction plan and the result of the reduction" issued by director Qu Guirong and supervisor Dong Chunhong respectively. As of the date of issuance of the notice letter, director Qu Guirong and supervisor Dong Chunhong reduced their holdings by 0 shares and 1000 shares respectively through centralized bidding transactions, and the implementation time of the reduction plan has expired.
(): It is planned to purchase 100% equity of Hunan Persimmon Bamboo Garden Nonferrous Metals Co., Ltd. by issuing shares and paying cash
China Tungsten High-tech announced that the company intends to purchase the 100% equity of Hunan Persimmon Bamboo Garden Nonferrous Metals Co., Ltd. jointly held by Minmetals Tungsten Industry Group Co., Ltd. and Hunan Woxi Mining Investment Co., Ltd. by issuing shares and raising supporting funds to no more than 35 specific investors. This reorganization is expected to constitute a major asset reorganization as stipulated in the "Measures for the Administration of Major Asset Restructuring of Listed Companies", and also constitutes a company related transaction. This reorganization does not constitute a reorganization and listing. This transaction will not lead to a change in the actual controller of the company.
The shareholders’ meeting will be held on March 26 to consider the proposal to acquire all the shares of Zhengzhou Jimei by cash and related party transactions
Langzi shares announced that the first extraordinary general meeting of shareholders will be held on March 26, 2024, and the online voting will be held on the same day. The equity registration date is March 14, and investors who hold Langzi shares after the market closes on that day can participate in the voting.
Meeting place: 16th Floor Conference Room, Building 1, Courtyard 3, Dajiaoting South Street, No. 27, Xidawang Road, Chaoyang District, Beijing (Langzi Building).
The shareholders’ meeting audited a total of one proposal, as follows:
1. Proposal on the cash acquisition of all the shares and related transactions of Zhengzhou Jimei.
Henghui Security: the actual 3.76 million shares will be listed on March 11
() Issue a prompt announcement on the partial lifting of the restrictions on the sale of the issued shares before the initial public offering and listing for circulation. The number of restricted shares listed and circulated this time is 10 million shares, accounting for 6.8693% of the company’s total share capital. The actual number of shares that can be listed and circulated is 3.76 million shares. The listing and circulation date is March 11, 2024 (Monday).
Liangxin plans to invest 26 million yuan in a holding subsidiary to promote the development of intelligent power distribution business
() Announcement, the company intends to jointly invest with Shanghai Zhuyong Enterprise Management Partnership (Limited Partnership) (abbreviation: "Zhuyong Enterprise"), Shanghai Zhuyong Enterprise Management Partnership (Limited Partnership) (abbreviation: "Zhuyong Enterprise"), Shanghai Zhuzhi Enterprise Management Partnership (Limited Partnership) (abbreviation: "Zhuzhi Enterprise") to establish Liangyun Zhihui (Guangdong) Co., Ltd. (tentative name, the final name shall be subject to the name approved by the registration authority, abbreviation: "Joint Venture Company"). The registered capital of the joint venture company is tentatively 50 million yuan, of which the company’s capital contribution is 26 million yuan, and the shareholding ratio is 52%. The joint venture company will be included in the scope of the consolidated statement.
In view of the future market opportunities for the in-depth electrification of various industries and the landing of the dual-carbon target, in order to seize the window period of the intelligent power distribution market and enhance the company’s comprehensive competitiveness, after careful research, the company decided to invest in the establishment of a joint venture company to develop intelligent power distribution related businesses. In the future, the joint venture company will focus on intelligent power distribution business, carry out innovation and optimization around the business model of intelligent power distribution, continue to increase the development of technology and product ecology, improve sales capabilities and delivery capabilities, promote the industrialization of R & D results, promote the rapid development of the company’s intelligent power distribution business, and enhance the company’s comprehensive market competitiveness and brand influence.
Jinling Sports: Li Jiangang, director and general manager, plans to increase his holdings by 10 million yuan – 20 million yuan
() announcement, director and general manager Li Jiangang intends to increase holdings 10 million yuan – 20 million yuan.
Precision Eye launched the "Double Improvement of Quality and Return" action plan
() At noon on March 7, the announcement on promoting the "double improvement of quality returns" action plan was disclosed, and it is planned to commit to the high-quality development of the company’s operation and the improvement of the level of sustainable development from five measures, and actively maintain market stability.
The company said that it will continue to focus on its main business, adhere to its medical attributes, and build long-term value. On the basis of the company’s successful investment and operation of 28 ophthalmic hospitals and 3 ophthalmic outpatient departments in 21 major cities in China, in the future, the company will continue to implement the development strategy of "national chain + intra-city integration", adhere to both endogenous growth and extension development, not only practice internal skills, strengthen refined management methods, enhance profitability and core competitiveness, but also use the capital markets platform to carry out mergers and acquisitions, further expand the layout in major cities across the country, and consolidate and increase the market share in advantageous regions, while maximizing the diagnosis and treatment needs of patients for eye health.
At the same time, the company will pay attention to medical innovation-driven, promote service and product technology upgrades. Improve the company’s internal governance, promote the company’s sustainable development, deeply practice the ESG concept, actively improve the level of ESG governance, and help the company’s high-quality sustainable development.
In addition, the company will effectively improve the level of information disclosure, establish a matrixed investor relations channel, and convey the intrinsic value of the company. Investor-oriented, focusing on investor returns, and working with investors to achieve a dynamic balance between performance growth and shareholder returns. Build a "long-term, stable and sustainable" shareholder value return mechanism to ensure that shareholders can effectively enjoy the company’s development results. (Tian Limin)
Li Jiangang, general manager of Jinling Sports, plans to increase the company’s shares from 10 million yuan to 20 million yuan
Jinling Sports announced that Mr. Li Jiangang, the director and general manager of the company, based on his confidence in the future development of the company and the recognition of long-term investment value, enhances investor confidence, and plans to increase his holdings of the company’s shares within 6 months from the date of disclosure of this announcement. The total amount of the proposed increase is not less than RMB 10 million yuan, not higher than RMB 20 million yuan, and the source of funds required for the increase is equity fund.
Jinling Sports: Directors plan to increase their shares by 10 million yuan to 20 million yuan
Jinling Sports announced on the evening of March 7 that Li Jiangang, the director and general manager of the company, based on his confidence in the company’s future development and the recognition of long-term investment value, enhanced investor confidence and planned to increase his holdings of the company’s shares. The total amount of the proposed increase is not less than 10 million yuan, not higher than 20 million yuan. The source of funds required for the increase is equity fund. The increase plan does not set a fixed price or price range.
Luoping Zinc Power: Fuller Lead-Zinc Mine Suspends Production
() Announcement, the company received the "Notice of Suspension of Production" issued by the Luoping County Emergency Management Bureau on March 7, 2024, because the company’s Fuller Lead-Zinc Mine Safety Production License (valid period from March 7, 2021 to March 6, 2024) has expired. According to the "Safety Production Law", "Safety Production License Regulations" and other relevant laws and regulations, all production activities will be stopped from now on, and production can only be resumed after going through the extension formalities and reporting for approval. According to the suspension notice, the company’s Fuller Lead-Zinc Mine will stop all production activities from now on.
Jiuan Medical has repurchased 3.08% of the shares at a cost of about 607 million yuan
() announced that as of March 7, 2024, the company through the stock repurchase special securities account to the centralized auction transaction accumulated the number of repurchased shares of the company 15.0562 million shares, accounting for 3.08% of the company’s total share capital, the highest transaction price is 41.277 yuan/share, the lowest transaction price is 39.42 yuan/share, the total amount paid is RMB 607 million yuan.
Luoping Zinc Power: Fuller Lead-Zinc Mine Suspension, Expected to Have Little Impact on Company Operations
Luoping Zinc and Electricity Announcement, the company received the "Notice of Suspension of Production" issued by the Luoping County Emergency Management Bureau on March 7, 2024. The reason is that the valid period of the safety production license of the company’s Fuller Lead-Zinc Mine is from March 7, 2021 to March 6, 2024, which has now expired. According to the "Safety Production Law", "Safety Production License Regulations" and other relevant laws and regulations, all production activities will be stopped from now on, and production can only be resumed after going through the extension procedures and reporting for approval. According to the suspension notice, the company’s Fuller Lead-Zinc Mine will stop all production activities from now on. According to the preliminary estimate of the mine’s production volume in recent years, this suspension has little impact on the company’s operations.
() The subsidiary plans to 2113.65 million yuan to participate in the special project of Guangzhou Gongchuangde Storage and invest in Guangzhou Zhiguang Energy Storage
Desai Battery announced that Huizhou Desai Battery Co., Ltd. (referred to as "Huizhou Battery"), a wholly-owned subsidiary of the company, signed the "Guangzhou Gongchuang Dereserve Equity Investment Fund Partnership (Limited Partnership) Partnership Agreement" with Guangzhou Gongchuang Dereserve Private Offering Fund Management Co., Ltd. (referred to as "Gongchuang Huiji") on March 7, 2024, and jointly invested in the establishment of Guangzhou Gongchuang Dereserve Equity Investment Fund Partnership (Limited Partnership) (tentative name). The total subscribed capital of the partnership is 2135.00 million yuan, of which Huizhou Battery, as a limited partner, subscribed 2113.65 million yuan in equity fund, with a capital contribution ratio of 99.00%; Gongchuang Huiji, as a general partner, subscribed capital contribution of 213,500 yuan, with a capital contribution ratio of 1.00%.
According to the announcement, the partnership will invest in Guangzhou Zhiguang Energy Storage Technology Co., Ltd. for special projects. Guangzhou Zhiguang Energy Storage Technology Co., Ltd. is mainly engaged in the research and application of industrial technology in the field of energy storage. It provides customers with energy storage technology consulting, energy storage system integration, energy storage equipment sales and other businesses in the technical fields of electrochemical energy storage, mechanical (flywheel) energy storage and super capacitor energy storage. It can also provide core key technologies and equipment such as energy storage battery PACK integration, BMS, PCS and EMS for the majority of energy storage system integrators, and can provide battery and battery PACK testing technology services.
Desai Battery: The subsidiary plans to invest 2113.65 million yuan to participate in the establishment of an equity investment fund
Desai Battery announced on the evening of March 7 that Huizhou Desai Battery Co., Ltd. (referred to as "Huizhou Battery"), a wholly-owned subsidiary of the company, and Guangzhou Gongchuanghuiji Private Offering Fund Management Co., Ltd. signed the "Guangzhou Gongchuangde Reserve Equity Investment Fund Partnership (Limited Partnership) Partnership Agreement" to jointly invest in the establishment of Guangzhou Gongchuangde Reserve Equity Investment Fund Partnership (Limited Partnership) (referred to as "Partnership"). The total subscribed capital of the partnership is 21.35 million yuan. Among them, Huizhou Battery, as a limited partner, subscribed 2113.65 million yuan in equity fund subscription, with a capital contribution ratio of 99.00%. The partnership invests special projects in Guangzhou Zhiguang Energy Storage Technology Co., Ltd.
Tang Renshen: February pig sales 272,000 head
() Announcement, the company’s February 2024 pig sales 272,000 head (including commercial pigs 247,100 head, piglets 24,900 head), February 2023 pig sales 285,800 head (including commercial pigs 267,800 head, piglets 18,000 head), down 4.83%, down 17.12%; sales revenue totaled 399.82 million yuan, down 9.92%, down 3.44%.
Keming Foods: Holding subsidiary Xingjiang Pastoral sold 25,900 pigs in February
() Announcement, the holding subsidiary Xingjiang Pastoral sold 25,900 pigs in February, and the sales volume decreased by 39.31% month-on-month, down 52.39% year-on-year; the sales revenue was 27.2403 million yuan, and the sales revenue decreased by 43.71% month-on-month, down 49.47% year-on-year.
The controlling shareholder of Jujie Microfiber intends to increase the company’s shares by 15 million to 30 million yuan
Jujie Microfiber announced that Suzhou Jujie Investment Co., Ltd., the controlling shareholder of the company, plans to increase its holdings of the company’s shares through the means allowed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.) within the next 6 months from the date of the announcement, with a total proposed increase of not less than 15 million yuan and not more than 30 million yuan.
The general manager of Jinling Sports plans to increase the company’s shares by 10 million to 20 million yuan
Jinling Sports announced that Li Jiangang, the director and general manager of the company, plans to increase his holdings of the company’s shares within 6 months from the date of disclosure of the announcement, and the total amount of the proposed increase is not less than 10 million yuan and not more than 20 million yuan.
Keming Foods: Xingjiang Pastoral’s pig sales in February fell by 52.39% year-on-year.
Keming Food announced that the company’s holding subsidiary Xingjiang Pastoral sold 25,900 live pigs in February 2024, and the sales volume decreased by 39.31% month-on-month, a year-on-year decrease of 52.39%; the sales revenue was 27.2403 million yuan, and the sales revenue decreased by 43.71% month-on-month, a year-on-year decrease of 49.47%.
From January to February, the company sold 68,500 pigs, down 20.94% from the same period last year; the cumulative sales revenue was 75.6314 million yuan, down 23.86% from the same period last year.
Zuoli Pharmaceutical: The exclusive variety Lingze tablets are listed as the national second-level protected variety of traditional Chinese medicine
() Announcement, the company received the "Certificate of Traditional Chinese Medicine Protected Variety" issued by the State Drug Administration, and the company’s exclusive variety Lingze Tablets was listed as the national second-level protected variety of traditional Chinese medicine.
Tang Renshen: In February 2024, the sales revenue of live pigs was about 400 million yuan, a decrease of 3.44% compared with the previous month.
Tang Renshen announced on the evening of March 7 that the company’s pig sales in February 2024 were 272,000, down 4.83% year-on-year and 17.12% month-on-month; the total sales revenue was about 400 million yuan, down 9.92% year-on-year and 3.44% month-on-month. The cumulative pig sales in January-February 2024 were 600,200, up 15.85% year-on-year; the sales revenue was about 814 million yuan, up 1.07% year-on-year.
Jujie Microfiber: The controlling shareholder Jujie Investment plans to increase the company’s shares by 15 million yuan – 30 million yuan
On the evening of March 7, Jujie Microfiber announced that the board of directors of the company recently received the "notice letter on the plan to increase the company’s shares" issued by the controlling shareholder Suzhou Jujie Investment Co., Ltd. (hereinafter referred to as "Jujie Investment"). The company’s controlling shareholder Jujie Investment plans to increase the company’s shares within the next 6 months from the date of this announcement through the means allowed by the China Securities Regulatory Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.), with a total amount of not less than RMB 5 million yuan and not more than RMB 0 yuan.
Allianz sharp vision: March 7 to buy back the company’s shares 10,000 shares
On the evening of March 7, () announced that on March 7, 2024, the company repurchased 10,000 shares of the company for the first time through centralized bidding transactions, accounting for 0.01% of the company’s total share capital.
Garden Bio: The company’s share repurchase has been completed
On the evening of March 7, Garden Bio announced that on September 14, 2023, the company repurchased the company’s shares through a centralized auction transaction through a special securities account for share repurchase. As of March 6, 2024, the company had repurchased 9,307,200 shares through a centralized auction transaction through a special securities account for share repurchase, accounting for 1.69% of the company’s current total share capital. The company’s share repurchase has been completed.
Civil Explosion Optoelectronics: 289,533 shares of the company were repurchased on March 6
On the evening of March 7, () announced that on March 6, 2024, the company repurchased 289,533 shares of the company for the first time through the stock trading system of the Shenzhen Stock Exchange in a centralized bidding mode, accounting for 0.2766% of the company’s total share capital.
Rijiu Optoelectronics: Accumulated repurchase of 3,506,800 shares of the company
On the evening of March 7, () announced that from February 8 to March 6, 2024, the company repurchased a total of 3,506,800 shares of the company through a centralized auction transaction through a repurchase special securities account, accounting for about 1.25% of the company’s current total share capital.
Rambler: Buyback of company shares 320,000 on March 7
On the evening of March 7, Rambler announced that on March 7, 2024, the company repurchased 320,000 shares of the company in a centralized bidding mode for the first time through the special securities account for share repurchase, accounting for 0.0360% of the company’s total share capital.
Huamao shares: repurchased 3 million shares of the company on March 7
On the evening of March 7, () announced that on March 7, 2024, the company repurchased 3,000,000 shares of the company through a centralized auction transaction through a special securities account for share repurchase, accounting for 0.32% of the company’s current total share capital.
Tofulong: Professional technology serves biomedicine and helps the development of human health
On March 7, () released an announcement on the "Double Improvement of Quality Return" action plan. The company said that after 30 years of development, it has grown into a comprehensive pharmaceutical equipment service provider that provides pharmaceutical processes, core equipment, and system engineering overall solutions for global pharmaceutical companies. With its competitive advantages in the industry such as technological innovation, perfect sales network layout, leading brand influence, and comprehensive solution services, the company is in a leading position in the field of domestic pharmaceutical equipment, and continues to narrow the gap with international leaders. While exploring overseas markets, it gradually realizes domestic substitution.
Yingke Medical: Give full play to the company’s comprehensive competitive advantages and develop into a global industry leader
On March 7, () issued an announcement on the "Double Improvement of Quality Return" action plan. The company said that it has accumulated more than 10 years of R & D and production experience, and has fully integrated hardware, software, infrastructure and the company’s proprietary technology and expertise. As of June 30, 2023, the company has completed 8 self-developed and self-produced projects, and new products cover 9 product categories and more than 60 product series.
Xingqi Eye Medicine: Will continue to increase investment in research and development to improve the product layout in various fields of ophthalmology
On March 7, () issued an announcement on the "Double Improvement of Quality and Return" action plan. The company said that since its establishment, it has always attached importance to the research and development of new products, and will develop new products with independent intellectual property rights as the company’s goal of continuous progress and innovation. R & D investment has increased year by year. In the past three years, the company’s R & D investment has been 84 million yuan, 118 million yuan, and 190 million yuan, accounting for 12.13%, 11.47%, and 15.22% of operating income respectively. After years of development, the company’s R & D center has seven process technology platforms such as conventional ophthalmic preparations, ophthalmic gels, and sustained-release preparations, as well as evaluation technology platforms such as quality research, pharmacological pharmacogenesis research and drug packaging material research.
Shouhang Hi-Tech: Signed a 429 million yuan solar thermal + photovoltaic integrated project equipment service supply contract
Recently, the company and China Energy Construction Group Northwest Power Construction Engineering Co., Ltd. signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project to provide contract equipment and services. The total contract amount is RMB 429 million yuan.
Keming food: holding subsidiary Xingjiang pastoral pig sales revenue in February 2724.03 million yuan, down 43.71%
Keming Food announced on the evening of March 7 that the holding subsidiary Xingjiang Pastoral sold 25,900 pigs in February 2024, and the sales volume decreased by 39.31% month-on-month and 52.39% year-on-year; the sales revenue was 2724.03 million yuan, and the sales revenue decreased by 43.71% month-on-month and 49.47% year-on-year. From January to February 2024, the company sold 68,500 pigs cumulatively, down 20.94% from the same period last year; the cumulative sales revenue was 75.6314 million yuan, down 23.86% from the same period last year.
Jilin Aodong issued 2 billion yuan medium-term notes accepted for registration
() Announcement, the company recently received the "Notice of Acceptance of Registration" issued by the China Interbank Market Dealers Association (China Market Association Note [2024] MTN208), the Dealers Association decided to accept the company’s medium-term note registration, the company’s medium-term note The registration amount is 2 billion yuan, and the registration amount is valid within 2 years from the date of signing the notice.
Shouhang Hi-Tech: Signed a 430 million yuan solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract
Shouhang Hi-Tech announced that the company and China Energy Construction Group Northwest Power Construction Engineering Co., Ltd. signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating system procurement contract", the company for Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating system) to provide contract equipment and services, the total contract amount 430 million yuan.
Shouhang Hi-Tech: Signed a 429 million yuan solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract
Shouhang Hi-Tech announced that recently, the company (hereinafter referred to as the "seller") and China Energy Construction Group Northwest Electric Power Construction Engineering Co., Ltd. (referred to as the "buyer") signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating heat collection system) to provide contract equipment and services. The total contract amount (tax included) is RMB 429 million yuan.
Luoxin Pharmaceutical and Shenzhen Unknown Jun have reached a strategic cooperation on the commercialization of intestinal microbiota transplantation (FMT)
() Announcement: On March 7, 2024, the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed a "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun and/or its affiliates will transplant their intestinal flora into medical technology authorized companies and/or their affiliates to carry out exclusive commercialization cooperation within the scope of cooperation areas and channels agreed upon by both parties, including but not limited to distribution, sales, promotion, etc.
The specific content of cooperative medical technology is the intestinal flora transplantation project ("FMT"), which involves wrapping fecal bacteria lyophilized powder or fecal bacteria particles in capsules and entering the human intestine by oral administration; or transplanting fecal bacteria isolated from the feces of healthy people into the intestine by nasal feeding, gastric tube insertion, and digestive endoscopic spraying, so as to restore the dynamic balance of intestinal flora, so as to achieve the purpose of treating various intestinal diseases caused by intestinal flora imbalance.
The announcement said that the company has long focused on the digestive field. This time, the company signed a "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun to reach a strategic cooperation on the commercialization of intestinal microbiota transplantation ("FMT"), which will help the company further improve its strategic layout in the digestive field and enhance its comprehensive competitiveness.
Zuoli Pharmaceutical: Lingze Tablets received the certificate of protected varieties of traditional Chinese medicine
Zuoli Pharmaceutical announced that the company has received the "Certificate of Traditional Chinese Medicine Protected Variety" issued by the State Drug Administration. The company’s exclusive variety Lingze Tablets is listed as the national second-level protected variety of traditional Chinese medicine, and the protection period is from March 1, 2024 to March 1, 2031.
Shennong Technology’s application is withdrawn and the application documents are added by summary procedure
() Announcement, on March 7, 2024, the company issued shares to specific objects by summary procedure in 2023, and the sponsor submitted to the Shenzhen Stock Exchange an application for withdrawing the application documents of Hainan Shennong Technology joint stock company to issue shares to specific objects by summary procedure.
The company’s current production and operation are normal, and it will also actively promote the purchase and sale of rapeseed and other businesses to promote the large-scale development of the company’s rapeseed seed business. The withdrawal of the application documents for issuing shares to specific objects through the simplified procedure will not have a significant impact on the company’s normal production and operation and sustainable and stable development, and will not harm the interests of the company and shareholders, especially minority shareholders.
Capital Airlines Hi-Tech signed a major contract related to 429 million yuan
Shouhang Hi-Tech announced that recently, the company (the "seller") and China Energy Construction Group Northwest Electric Power Construction Engineering Co., Ltd. (the "buyer") signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating heat collection system) to provide contract equipment and services, the total contract amount (tax included) 429 million yuan, accounting for about 65.73% of the company’s 2022 annual operating income.
The shareholders’ meeting will be held on March 25 to consider proposals to change the company’s registered capital, amend the company’s articles of association, and handle the registration of industrial and commercial changes
Canaan Smart announced that the first extraordinary general meeting of shareholders will be held on March 25, 2024, and online voting will be held on the same day. The equity registration date is March 20, and investors who hold Canaan Smart shares after the market closes on that day can participate in the voting.
Venue: Ningbo Canaan intelligent electric joint stock company conference room, 315 Kaiyuan Road, Cixi City, Zhejiang Province.
The shareholders’ meeting audited a total of one proposal, as follows:
1. "Proposal on Changing the Registered Capital of a Company and Amending and Handling the Registration of Industrial and Commercial Changes".
Guangdong Construction Engineering subsidiary jointly won the bidding for Guangzhou to develop Tianjin Xiqing District 750MW wind power project
() Announcement, Guangdong Yuantian Engineering Co., Ltd. (referred to as "Yuantian Company"), a wholly-owned subsidiary of the company, received the "Notice of winning the bidding" from Guangzhou Trading Group Co., Ltd.
The "win the bidding notice" determines that the consortium formed by Yuantian Company (member party) and China Energy Construction Group Guangdong Thermal Power Engineering Co., Ltd. (organizer) is the win the bidding unit of " () Tianjin Xiqing District 750MW Wind Power Project EPC General Contracting [JG2024-0695]". The contract content is the code packet of the released version specified in the invite tenders document. The winning bid price of the project is 4.893 billion yuan, and the total construction period of the project is 18 months. Among them, the construction task undertaken by Yuantian Company is about 1.846 billion yuan.
According to the invite tenders document, the project plans to install 120 single-unit capacity 6.25MW wind turbines, with an installed capacity of 750MW, and two new 220kV boosting stations. According to the joint tender agreement of the consortium, Yuantian Company is responsible for the civil engineering of 750MW wind turbines (including hoisting platforms, fan foundations), all road engineering construction within the scope of the project, the renovation of Lishuang Highway, all project temporary land use and related compensation for the project, environmental protection engineering, soil and water conservation engineering, labor safety and industrial hygiene engineering, safety monitoring engineering and other related procedures; China Energy Construction Group Guangdong Thermal Power Engineering Co., Ltd. is responsible for the survey and design, all fan units, tower cylinders, box transformers, high and low voltage cables, all equipment and materials procurement of 220KV booster stations, 750MW fan unit hoisting, all 35KV collector lines construction and safety engineering (including tower materials, wires, fittings and other materials procurement), 220KV booster station construction and safety engineering, 220KV outgoing line and opposite side interval renovation engineering materials procurement, construction and safety construction. Special project report preparation, special project acceptance, equipment supervision.
Guangdong Construction Engineering: Subsidiaries jointly won the bidding of Guangzhou Development Tianjin Xiqing District 750MW wind power project EPC general contracting project
Guangdong Construction Engineering announced on the evening of March 7 that the consortium formed by Guangdong Yuantian Engineering Co., Ltd. (referred to as "Yuantian Company") (member party) and China Energy Construction Group Guangdong Thermal Power Engineering Co., Ltd. (organizer) is the winning unit of the EPC general contract [JG2024-0695] for the "Guangzhou Development Tianjin Xiqing District 750MW Wind Power Project". The winning bid price is about 4.893 billion yuan, and the total construction period of the project is 18 months. Among them, the construction task undertaken by Yuantian Company is about 1.846 billion yuan. According to the invite tenders document, the project plans to install 120 single-machine capacity 6.25MW wind turbines, with an installed capacity of 750MW, and build 2 new 220kV booster stations.
ST has a tree: plans to transfer 17% stake in CCCC New Energy to Lu Yicheng
ST Youkeshu announced that in order to comprehensively focus on the main business of cross-border e-commerce, optimize the investment structure, and further improve the profitability of assets, Youkeshu Technology joint stock company (referred to as "Youkeshu" or "Company") plans to transfer the 17% equity (registered capital contribution 34 million yuan) of Jiangsu CCCC New Energy Technology Co., Ltd. (referred to as "CCCC New Energy") held by its wholly-owned subsidiary Nanjing Keshu Technology Co., Ltd. (referred to as "Nanjing Keshu") to Lu Yicheng at a price of 40 million yuan. After the completion of this transfer, Nanjing Keshu will no longer hold the equity of CCCC New Energy.
China-UK Technology 48.405 million Restricted Shares Available for Circulation on March 13
() Announcement, the number of shares issued before the company’s initial public offering is 48.405 million shares, accounting for 64.37% of the company’s total share capital, and the date of listing and circulation is March 13, 2024.
Fan Zhihong and Chen Haibing, directors of Jinbei Electric, have reduced their holdings by a total of 3.29 million shares
() announcement, the company’s director and vice president Fan Zhihong, Chen Haibing reduction plan period has expired, a total reduction of the company’s shares 3.29 million shares.
Huapengfei: The company signed a strategic cooperation framework agreement with the joint stock company of Ririshun Supply Chain Technology
() Announcement, the company signed a strategic cooperation framework agreement with the Ririshun Supply Chain Technology joint stock company.
Huakai Yibai granted 16.722 million restricted shares at a grant price of 9.82 yuan/share
() announcement, the company 2024 restricted stock incentive plan provisions of the restricted stock grant conditions have been achieved, the company deliberated and passed the "on the grant of restricted stock to the incentive object", agreed and determined that the incentive plan restricted stock grant date is March 7, 2024, to meet the conditions of 114 incentive objects granted 16.722 million shares of restricted stock, the grant price is 9.82 yuan/share.
Huapengfei: Signed a strategic cooperation framework agreement with Ririshun Supply Chain
Huapengfei announced on the evening of March 7 that the company and Ririshun Supply Chain Technology joint stock company (referred to as "Ririshun Supply Chain") have their own resources and advantages in the field of supply chain, and are committed to commercial cooperation in cross-border integrated logistics. After friendly negotiation between the two sides, it was decided to establish a strategic partnership and sign the "Strategic Cooperation Framework Agreement".
Fu Xin Ping An Bank Director Qualifications Approved
Ping An Bank issued an announcement, recently, Ping An Bank joint stock company received the "State Financial Supervision and Administration Administration on Ping An Bank Fu Xin qualification", the State Financial Supervision and Administration approved Fu Xin Ping An Bank joint stock company director qualifications.
Luoxin Pharmaceutical and micro-ecological R & D enterprise Unknown Jun reached a strategic cooperation
On March 7, Luoxin Pharmaceutical announced that the joint stock company of Luoxin Pharmaceutical Group (hereinafter referred to as "the company") and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed the "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun will hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercialization cooperation within the agreed cooperation area and channel scope, and the two sides will establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.
The application prospect of microbiota transplantation is huge, and the industry is leading
The intestinal microbiota is called the "hidden organ" of the human body. More and more studies have found that the intestinal microbiota has an important connection with the occurrence of human health and diseases. When the intestinal microbiota is unbalanced, it will lead to the occurrence of many diseases. There are as many as 85 indications related to the treatment of intestinal microbiota. By regulating the intestinal microbiota, it can affect the health of the human body. The intestinal microbiota can not only become drugs but also serve as new drug targets, so the intestinal microbiota has great application prospects in the treatment of certain diseases. At present, the intestinal microbiota transplantation (FMT) has gradually become one of the most cutting-edge and hot research fields in the industry. Intestinal microbiota transplantation is to transplant the functional flora in the intestines of healthy people into patients to rebuild a healthy intestinal microbiome, in order to restore the diversity of intestinal flora, improve the balance of intestinal flora, and achieve the treatment of intestinal and parenteral diseases.
Shenzhen Unknown Junzheng, which has reached a cooperation with Luoxin Pharmaceutical this time, is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Unknown Junzheng has built a leading micro-ecological strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing. It is worth mentioning that Unknown Jun also has an industry-leading micro-ecological pipeline matrix, many of which are First-in-class, and have completed the layout in the fields of cancer, nervous system, digestive system, immune system and other diseases, covering all mainstream drug forms such as formula bacteria, genetically engineered microorganisms, bacterial metabolites, and enterobacteria transplantation. The pipeline layout and promotion capabilities are world-leading. He is the first (only) FMT/enterobacteria transplantation management system in Asia that meets FDA requirements. The production process strictly follows GMP specifications; the production environment is cleaner than the industry standard; the raw and auxiliary materials used are all pharmaceutical grade to ensure the safety of the product.
The barriers in the digestion field are profound, and the commercialization experience and advantages of established pharmaceutical companies are obvious
As an established enterprise that has been deeply involved in the pharmaceutical industry for more than 30 years, Luoxin Pharmaceutical has long focused on unmet clinical needs in core disease fields such as digestion, respiration, and anti-tumor. It has listed more than 10 dosage forms, more than 150 varieties, and more than 300 product specifications, forming a rich and competitive product portfolio. The core products are in a leading position in the market for digestive and respiratory diseases. According to IQVIA2023 data, the company’s digestive products, omeprazole enteric-coated capsules, rabeprazole sodium for injection, and lansoprazole for injection, have ranked first in the market share. It is worth noting that the company’s Class 1 innovative drug Tegorasan Tablets is the first self-developed potassium ion competitive acid blocker (P-CAB) in our country. It has been identified as a major special project of national "major new drug creation" science and technology. Currently, two indications have been approved for marketing: reflux esophagitis and duodenal ulcer. The third indication "combined with appropriate antibacterial therapy to eradicate Helicobacter pylori" has been accepted by the State Drug Administration. Recently, the results of the Phase III clinical study of pukanapeptide tablets for the treatment of functional constipation have reached the main efficacy endpoint. In addition, Tegorasan injection is also under development, and there is no similar injection product on the market worldwide. In the field of digestion, whether it is the esophagus of the upper digestive tract, the stomach or the intestines, gallbladder and pancreas of the lower digestive tract, it is the key direction of the company’s future expansion, and is committed to becoming an active leader in the ecosystem of China’s digestive field. Luoxin Pharmaceutical has built a professional commercialization team since the second half of 2021, and has the management experience of localizing the sales system of multinational pharmaceutical companies and the commercialization experience of innovative drugs. It has realized the core product of digestive system, Tegola raw tablets, in the early stage of listing, which has enabled thousands of doctors to quickly gain drug experience accumulation. It was approved to be included in the national medical insurance catalogue at a reasonable price in the same year. The following year of listing,
Commercialization Blue Ocean Domestic policy support Cooperation Complementary advantages of both parties Deeply empowered
Since the launch of the Human Microbiome Project in the United States in 2007, the development of micro-ecological medicine and microbial-related technologies has entered an accelerated stage. A large number of microbial pharmaceutical star companies have emerged. According to incomplete statistics, there are more than 50 micro-ecological pharmaceutical companies in the world, and multinational pharmaceutical giants such as Pfizer, Roche, Johnson & Johnson have also laid out micro-ecological pharmaceutical tracks. Intestinal microbiota transplantation research has grown rapidly since 2013 and has received more attention in recent years. There are more than 500 clinical trials related to intestinal microbiota transplantation registered internationally, involving indications including: pseudomembranous enteritis (Clostridium difficile infection), ulcerative colitis, Crohn’s disease, chronic functional diarrhea and constipation, diabetes, insomnia, obesity, autism, liver cirrhosis, allergic diseases, antibiotic resistance, anti-tumor drug resistance, depression, Parkinson’s disease and many other diseases. The patient base is huge. According to public information on the domestic government website, "Microbiota transplantation is becoming a new track in the field of biomedicine, and the global size of the market segment is about 50 billion US dollars." The domestic micro-ecological pharmaceutical industry is in a stage of rapid start, and the future market space is extremely broad. Intestinal microbiota transplantation is expected to become the next explosive point of the pharmaceutical industry. In 2023, the "National Medical Service Technical Specification (2023 Edition) " announced by the National Health Commission officially included "intestinal microbiota transplantation" in the technical specification, supporting the rapid development of the industry.
Luoxin Pharmaceutical’s digestive field, whether it is the professionalism of the sales team or the department resources at the hospital end, has experienced the polishing and accumulation of time, and the commercialization ability is more advantageous. Unknown Jun is at the leading level in the field of intestinal flora transplantation (FMT) in terms of sample database, R & D capabilities and production process. This cooperation is Luoxin Pharmaceutical’s always-keen insight and forward-looking layout of market demand. The revolutionary significance and clinical value of intestinal flora transplantation as a diagnosis and treatment method will be realized through Luoxin Pharmaceutical’s commercialization capabilities covering hospitals at all levels across the country and Unknown Jun’s self-developed precision enterobacteria transplantation solutions, and jointly explore the domestic blue ocean market opportunities.
Note: Unknown Jun CMC production workshop
(): The company and its wholly-owned subsidiaries signed the "Cooperation Framework Agreement" with Gree Supply Chain and Gechuang Supply Chain
Keheng share announcement, the company and its wholly-owned subsidiaries Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng, Haoneng Technology and Gree Supply Chain, Gechuang Supply Chain signed the "Cooperation Framework Agreement". Gree Supply Chain and Gechuang Supply Chain gave Jiangmen Keheng, Yingde Keheng, Zhuhai Keheng, Zhuhai Haoneng and Haoneng Technology a total of RMB 650 million for the procurement of raw materials.
Tang Renshen: February pig sales revenue of about 400 million yuan
Tang Renshen announced that the company’s pig sales in February 2024 272,000, down 4.83% year-on-year and 17.12% month-on-month; sales revenue totaled 399.82 million yuan, down 9.92% year-on-year and 3.44% month-on-month. From January to February 2024, the cumulative pig sales volume was 60,200, up 15.85% year-on-year; sales revenue was 81.39 million yuan, up 1.07% year-on-year.
Diou Home Furnishing Shareholder Sichuan Development Fund reduced its holdings by 41,100 shares
() Announcement that as of the expiration date of the reduction plan, the shareholder Sichuan Development Fund has reduced the company’s shares 41,100 shares through centralized bidding mode, accounting for 0.01% of the company’s total share capital. As of the disclosure date of this announcement, the shareholder Sichuan Development Fund’s reduction plan has been implemented.
Pulo Pharmaceutical announced the 2023 annual rights distribution plan, proposing to pay 3.16 yuan for 10 grants
() issued an announcement on March 8, the company’s 2023 annual equity distribution plan is as follows: based on the total share capital 1.1693236 billion shares, cash dividends of 3.16 yuan will be distributed to all shareholders for every 10 shares, and a total of 370 million yuan will be distributed.
According to the 2023 annual performance report of Prologis Pharmaceutical, the company’s operating income 11.474 billion yuan, an increase of 8.81% year-on-year; net profit attributable to shareholders of listed companies 1.055 billion yuan, an increase of 6.69% year-on-year; basic earnings per share of 0.90 yuan, the same period last year was 0.84 yuan.
The main business of Pullo Pharmaceutical joint stock company covers the R & D, production and sales of API intermediates, innovative drug R & D and production services (CDMO), preparations, etc., as well as import and export trade business. API intermediate business includes cephalosporin series, penicillin series, psychiatric series, cardiovascular and cerebrovascular series and veterinary drug API intermediate series; innovative drug R & D and production services (CDMO) include R & D services, commercial human drug projects, commercial veterinary drug projects and other commercializations; preparation business includes anti-infective, cardiovascular and cerebrovascular, psychiatric and anti-tumor categories. The company is a large comprehensive pharmaceutical enterprise integrating research, development and production of APIs, preparations and pharmaceutical intermediates. It is a national key high-tech enterprise and a key enterprise in the pharmaceutical industry of Zhejiang Province. It has been awarded the title of "Top Ten Enterprises" in the pharmaceutical industry of Zhejiang Province for nine consecutive years, and the title of AAA credit rating enterprise of Bank of China in Zhejiang Province for ten consecutive years. It has been ranked among the largest taxpayers in Zhejiang Province for five consecutive years. The trademark of "Kangyu" is a famous trademark in Zhejiang Province.
(Source of data: iFinD)
Keheng shares will hold a shareholders’ meeting on March 25 to consider the proposal to sign a cooperation framework agreement and related party transactions
Keheng shares announced that the second extraordinary general meeting of shareholders will be held on March 25, 2024, and the online voting will be held on the same day. The equity registration date is March 18, and investors who hold Keheng shares after the market closes on that day can participate in the voting.
Venue: Jiangmen City Jianghai District Jiaotou Jiaoxing South Road No. 22 Jiangmen City Keheng Industrial joint stock company 3 floor conference room.
The shareholders’ meeting audited a total of one proposal, as follows:
1. Proposal on Signing and Related Transactions.
Jinling Sports: General Manager Li Jiangang plans to increase his stake in the company from 10 million yuan to 20 million yuan
On the evening of March 7, Jinling Sports announced that the company received the "Notice Letter of Share Increase Plan" issued by Mr. Li Jiangang, director and general manager of the company on March 7, 2024. Mr. Li Jiangang, director and general manager of the company, plans to increase his holdings of the company’s shares within 6 months from the date of disclosure of this announcement. The total amount of the proposed increase is not less than 10 million yuan and not more than 20 million yuan. The source of funds required for the increase is equity fund.
Pangang Group: 22 Pangang 01 will pay interest on March 11
On March 7, Pangang Group Co., Ltd. issued an interest payment announcement that it will pay interest for the period from March 10, 2023 to March 9, 2024 on March 11, 2024.
According to the interest payment plan, the coupon rate of the current bond variety 1 "22 Pangang 01" is 3.59%. This interest payment is RMB 35.90 (tax included) per lot (face value 1,000 yuan) of "22 Pangang 01". After tax deduction, the actual per-lot interest paid by individuals and securities investment fund bondholders is 28.72 yuan; the actual per-lot interest paid by non-resident enterprises (including QFII and RQFII) is 35.90 yuan.
Yitong Century: Re-identified as a high-tech enterprise
On the evening of March 7, () announced that recently, the company received the "High-tech Enterprise Certificate" jointly issued by the Guangdong Provincial Department of Science and Technology, the Guangdong Provincial Department of Finance, and the Guangdong Provincial Taxation Bureau of the State Administration of Taxation. This is a re-identification of the company’s original high-tech enterprise certificate after the valid period expires.
Longquan Shares: The implementation of this share repurchase plan has been completed
On the evening of March 7, () announced that the company implemented the share repurchase for the first time on February 28, 2024 through the repurchase special securities account in the form of centralized bidding transactions. As of March 6, 2024, the company has repurchased a total of 3290,000 shares of the company through the share repurchase special account in the form of centralized bidding transactions, accounting for 0.58% of the company’s total share capital. So far, the company’s share repurchase plan has been implemented.
Jiuan Medical: Accumulated repurchase of 15056236 shares
On the evening of March 7, Jiuan Medical announced that on February 8, 2024, the company repurchased the company’s shares in a centralized bidding mode for the first time through the special securities account for share repurchase. As of March 7, 2024, the company repurchased a total of 15056,236 shares of the company’s shares in a centralized bidding transaction through the special securities account for share repurchase, accounting for 3.08% of the company’s total share capital.
Jinling Sports: General Manager plans to increase holdings 10 million yuan – 20 million yuan
On March 7, Jinling Sports announced that Li Jiangang, the general manager of the company, plans to increase the company’s shares, and the total amount of the proposed increase is not less than 10 million yuan, not higher than 20 million yuan.
Copyright Daily Economic News
Luoxin Pharmaceutical: Signed a strategic cooperation framework agreement with Shenzhen Unknown Jun
On March 7, Luoxin Pharmaceutical announced that the company signed the "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun. Shenzhen Unknown Jun and/or its affiliates will transfer their intestinal flora transplantation medical technology authorized companies and/or their affiliates to carry out exclusive commercialization cooperation within the scope of cooperation areas and channels agreed upon by both parties, including but not limited to distribution, sales, promotion, etc.
Luoxin Pharmaceutical joins hands with Shenzhen Unknown Jun to further enrich the layout of the digestive tract
On March 7, Luoxin Pharmaceutical announced that the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed a "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun will hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercialization cooperation within the agreed cooperation area and channel scope between the two parties, and the two parties will establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.
Broad application prospects of microbiota transplantation
It is understood that the intestinal microbiota is known as the "hidden organ" of the human body, which is the normal microorganism of the human intestine. By regulating the intestinal microecology, it can affect the health of the human body. The intestinal microbiota can not only become a drug but also serve as a new drug target. Therefore, the intestinal microbiota has great application prospects in the treatment of certain diseases. At present, intestinal microbiota transplantation (FMT) has gradually become one of the most cutting-edge and popular research fields in the industry. Intestinal microbiota transplantation is to transplant the functional microbiota in the intestines of healthy people into patients to rebuild a healthy intestinal microbiota, so as to restore the diversity of intestinal microbiota, improve the balance of intestinal microbiota, and achieve the treatment of intestinal and extraintestinal diseases.
Shenzhen Unknown Junzheng, which has reached a cooperation with Luoxin Pharmaceutical this time, is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Shenzhen Unknown Junzheng has built a leading micro-ecological strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing. It is worth mentioning that Shenzhen Unknown also has an industry-leading micro-ecological pipeline matrix, many of which are first-in-class, and have completed the layout in the fields of cancer, nervous system, digestive system, immune system and other diseases, covering all mainstream drug forms such as formula bacteria, genetically engineered microorganisms, bacterial metabolites, and enterobacteria transplantation. The pipeline layout and promotion capabilities are world-leading, and it is the first (only) FMT/enterobacteria transplantation management system in Asia that meets FDA requirements.
The barriers in the field of digestive system are profound, and the commercialization experience and advantages of established pharmaceutical companies are obvious
As an established enterprise that has been deeply involved in the pharmaceutical industry for more than 30 years, Luoxin Pharmaceutical has long focused on the unmet clinical needs in the core disease fields such as digestion, respiration, and anti-tumor. It has listed more than 10 dosage forms, more than 150 varieties, and more than 300 product specifications, forming a rich and competitive product portfolio. The core products are in the leading position in the digestive system and respiratory system disease drug market. According to IQVIA2023 data, the company’s digestive system products, such as omeprazole enteric-coated capsules, rabeprazole sodium for injection, and lansoprazole for injection, rank first in the market share.
Luoxin Pharmaceutical has been building a professional commercialization team since the second half of 2021, and has the management experience of localizing the sales system of multinational pharmaceutical companies and the commercialization experience of innovative drugs. It has realized that the core product of digestive system, Tegola raw tablets, has enabled thousands of doctors to quickly gain drug experience in the early stage of listing, and was included in the national medical insurance catalog at a reasonable price in the year it was approved. The following year, it was listed, and the new commercialization speed of hospital access reached 1,000 and sales doubled.
Commercialization Blue Ocean Domestic policy support Cooperation Complementary advantages of both parties Deeply empowered
It is understood that since the launch of the Human Microbiome Project in the United States in 2007, the development of micro-ecological medicine and microbial-related technologies has entered an accelerated stage, and a large number of microbial pharmaceutical star companies have emerged. According to incomplete statistics, there are more than 50 global micro-ecological pharmaceutical companies, and multinational pharmaceutical giants such as Pfizer, Roche, Johnson & Johnson have also laid out micro-ecological pharmaceutical tracks. Intestinal microbiota transplantation research has grown rapidly since 2013, and has received more attention in recent years. There are more than 500 clinical trials related to enterobacteria transplantation registered internationally, involving indications including: pseudomembranous enteritis (Clostridium difficile infection), ulcerative colitis and many other diseases, with a large patient base. The public information on the domestic government website shows that "flora transplantation is becoming a new track in the field of biomedicine, and the global scale of the market segment is about 50 billion US dollars." The domestic micro-ecological pharmaceutical industry is in the stage of rapid start, and the future market space is extremely broad. Intestinal flora transplantation is expected to become the next flash point of the pharmaceutical industry. In 2023, the "National Medical Service Technical Specification (2023 Edition) " announced by the National Health Commission officially included "intestinal flora transplantation" in the technical specification to support the rapid development of the industry.
At present, Luoxin Pharmaceutical’s digestive system field, whether it is the professionalism of the sales team or the department resources at the hospital end, has experienced the polishing and accumulation of time, and the commercialization ability is more advantageous. Shenzhen Unknown Jun is at the leading level in the field of intestinal flora transplantation (FMT) in terms of sample database, R & D capabilities and production processes. This cooperation is Luoxin Pharmaceutical’s always-keen insight and forward-looking layout to market demand. The revolutionary significance and clinical value of intestinal flora transplantation as a diagnosis and treatment method will be realized through the commercialization ability of Luoxin Pharmaceutical covering hospitals at all levels across the country and the precision enterobacteria transplantation solution independently developed by Shenzhen Unknown Jun, and jointly explore the domestic blue ocean market opportunities. (Qi Hening)
Picture Note: Shenzhen Unknown Jun CMC Production Workshop
Dike Co., Ltd.: An advanced packaging and testing equipment has been patented and has not yet been applied to production
China Fortune Connect, March 7 – () announced that the company recently obtained a patent certificate issued by the State Intellectual Property Office, the patent name is an advanced packaging and testing equipment. The invention patent is the company’s technology research and development and technical reserves. The patent has not been applied to production and will not have a significant impact on the company’s near-term production and operation, but it will help the company to further improve the intellectual property protection system, give full play to the advantages of independent intellectual property rights, and form a continuous innovation mechanism to maintain the company’s technological leadership and enhance the company’s core competitiveness.
Xintian Pharmaceutical: plans to purchase 85.12% equity of Huilun Pharmaceutical by issuing shares
() Announcement that the company plans to purchase 85.12% of the shares of Huilun Pharmaceutical held by 88 shareholders of Huilun Pharmaceutical, including Dong Dalun, Dong Zhu and Hainan Qianyao, by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company.
Luoxin Pharmaceutical joins hands with Shenzhen Unknown Jun to expand the field of intestinal flora transplantation
On the evening of March 7, Luoxin Pharmaceutical announced that it had signed a "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun"), and Shenzhen Unknown Jun would hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercialization cooperation within the agreed cooperation areas and channels between the two parties.
At present, intestinal microbiota transplantation (FMT) has gradually become one of the most cutting-edge and hot research areas in the industry. Intestinal microbiota transplantation is the transplantation of functional microbiota from healthy people’s intestines into patients to rebuild healthy intestinal microbiota, in order to restore intestinal microbiota diversity, improve intestinal microbiota balance, and achieve the treatment of intestinal and extraintestinal diseases.
Shenzhen Unknown Junzheng, which has reached a cooperation with Luoxin Pharmaceutical this time, is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Unknown Junzheng has built a leading micro-ecological strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing. It is worth mentioning that Unknown also has an industry-leading micro-ecological pipeline matrix, many of which are first-in-class, and have completed the layout in the fields of cancer, nervous system, digestive system, immune system and other diseases, covering all mainstream drug forms such as formula bacteria, genetically engineered microorganisms, bacterial metabolites, and intestinal bacteria transplantation. The pipeline layout and propulsion capabilities are world-leading.
As an established enterprise that has been deeply involved in the pharmaceutical industry for more than 30 years, Luoxin Pharmaceutical has long focused on unmet clinical needs in core diseases such as digestion, respiration, and anti-tumor. It has listed more than 10 dosage forms, more than 150 varieties, and more than 300 product specifications, forming a rich and competitive product portfolio. The core products are in a leading position in the market for digestive and respiratory diseases. Since the second half of 2021, Luoxin Pharmaceutical has built a professional commercialization team. It has management experience in localization of sales systems of multinational pharmaceutical companies and commercialization experience in the landing of innovative drugs.
Intestinal microbiota transplantation research has grown rapidly since 2013, and has received more attention in recent years. More than 500 clinical trials related to intestinal microbiota transplantation have been registered internationally. In 2023, the "National Medical Service Technical Specification (2023 Edition) " announced by the National Health and Health Commission officially included "intestinal microbiota transplantation" in the technical specification, supporting the rapid development of the industry.
This cooperation is Luoxin Pharmaceutical has always maintained a keen insight into market demand and a forward-looking layout. The revolutionary significance and clinical value of intestinal flora transplantation as a diagnosis and treatment method are expected to be realized through the commercialization capabilities of Luoxin Pharmaceutical covering hospitals at all levels across the country and the precision enterobacteria transplantation solutions independently developed by Unknown Jun. (Nie Pin)
Wall Nuclear Materials: 2 subsidiaries were re-identified as high-tech enterprises
On the evening of March 7, () announced that the company’s holding subsidiary, Shanghai Kete New Materials joint stock company and Shanghai Changyuan Electronic Materials Co., Ltd. passed the re-identification of high-tech enterprises and recently received the "High-tech Enterprise Certificate".
Luoxin Pharmaceutical and Shenzhen Unknown have reached a strategic cooperation
On the evening of March 7, Luoxin Pharmaceutical announced that the joint stock company of Luoxin Pharmaceutical Group (hereinafter referred to as "the company") and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed the "Strategic Cooperation Framework Agreement" in Shenzhen, Shenzhen Unknown Jun will hold the intestinal flora transplantation (FMT) medical technology authorized company to carry out exclusive commercial cooperation within the agreed cooperation area and channel scope, and the two sides will establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.
Luoxin Pharmaceutical said that the company has been focusing on the digestive field for a long time. This time, the company signed the "Strategic Cooperation Framework Agreement" with Shenzhen Unknown Jun to reach a strategic cooperation on the commercialization of intestinal flora transplantation (FMT), which will help the company to further improve the strategic layout in the digestive field and enhance the company’s comprehensive competitiveness. This agreement is a framework document for the cooperation between the two parties. There are still uncertainties in the follow-up progress, and there are also uncertainties in the impact on the company’s current and future operating results. The signing and performance of this agreement will not affect the independence of the company’s business, and the company’s main business will not become dependent on the partners as a result of
It is reported that Shenzhen Unknown Jun is currently the industry-leading AI + BT microbiome research and product development platform, and a leader in the domestic micro-ecology field. According to its official website, Shenzhen Unknown Jun has built a leading microecology strain sample and data asset library, and created an international leading bioinformation analysis platform composed of four core platforms of AI drug discovery, algorithms, clinical analysis, and data/computing.
Chenzhan Optoelectronics: Accumulated repurchase of 2064,210 shares
On the evening of March 7, () announced that from March 1 to March 7, 2024, the company repurchased 2064,210 shares of the company in a centralized bidding mode through the special securities account for share repurchase, accounting for 1.26% of the company’s total share capital.
Jiahe Intelligent: The first repurchase of 140,400 shares
On the evening of March 7, () announced that on March 7, 2024, the company repurchased 140,400 shares of the company through a centralized auction transaction through a repurchase special securities account for the first time, accounting for 0.04% of the company’s current total share capital.
Luoxin Pharmaceutical and Shenzhen Unknown Jun signed a "Strategic Cooperation Framework Agreement" involving intestinal microbiota transplantation medical technology
On the evening of March 7, Luoxin Pharmaceutical announced that on March 7, the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. (hereinafter referred to as "Shenzhen Unknown Jun") signed a "Strategic Cooperation Framework Agreement" in Shenzhen. Shenzhen Unknown Jun and/or its affiliates will transplant their intestinal flora into medical technology authorized companies and/or their affiliates to carry out exclusive commercialization cooperation within the agreed cooperation areas and channels, including but not limited to distribution, sales, promotion, etc. Both parties agreed to establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.
It is understood that the specific connotation of intestinal flora transplantation medical technology is to wrap fecal bacteria lyophilized powder or fecal bacteria particles in capsules and enter the human intestine by oral administration; or transplant fecal bacteria isolated from the feces of healthy people through nasal feeding, gastric tube insertion, and digestive endoscopic spraying into the intestine to restore the dynamic balance of intestinal flora, so as to achieve the purpose of treating various intestinal diseases caused by intestinal flora imbalance.
Xintian Pharmaceutical plans to issue an additional 85.12% stake in Huilun Pharmaceutical, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical medicine"
Xintian Pharmaceutical announced that the company plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical joint stock company ("Huilun Pharmaceutical"), including Dong Dalun, Dong Zhu and Hainan Qianyao, by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the company. The price of the shares issued this time is 8.12 yuan/share. This transaction is expected to constitute a major asset restructuring.
It is reported that Huilun Pharmaceutical’s main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immune inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecology, andrology and other diseases. Through this transaction, the company will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical drugs", realizing rich integration of product structure, further expansion of therapeutic fields and upgrading of future innovative drug pipelines, and accelerating the establishment of a leading comprehensive pharmaceutical enterprise.
Oriental Seiko: No direct partnership with Nvidia
() Issued an announcement of abnormal stock trading fluctuations. The company has recently noticed that some media have listed the company as a "robot + Nvidia" concept stock. Many relevant media reports mention Guangdong Jiateng Robot Automation Co., Ltd., a shareholding company of Oriental Seiko. Oriental Seiko takes "intelligent equipment manufacturing" as the strategic core, focuses on the direction of high-end intelligent equipment manufacturing, and its main business layout is in the two fields of "intelligent packaging equipment" and "water power equipment". As of now, Oriental Seiko has no direct cooperative relationship with Nvidia. Based on Oriental Seiko’s shareholding ratio of Jiateng Robotics and the accounting treatment of the investment in Oriental Seiko’s consolidated financial statements, the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term.
Xintian Pharmaceutical plans to acquire 85.12% stake in Huilun Pharmaceutical and resume trading on March 8
On the evening of March 7, Xintian Pharmaceutical announced that it plans to purchase the 85.12% equity of Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical joint stock company (hereinafter referred to as "Huilun Pharmaceutical"), including Dong Dalun, Dong Zhu and Hainan Qianyao, through the issuance of shares.
According to the data, Huilun Pharmaceutical’s main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immune inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecology, andrology and other diseases. Xintian Pharmaceutical said that after the completion of this transaction, the company will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical drugs", realizing rich integration of product structure, further expansion of therapeutic fields and upgrading of future innovative drug pipelines, and relying on the integration with underlying assets to enhance the company’s Product Research & Development capabilities, market competitiveness, sustainable development capabilities and anti-risk capabilities, and accelerate the creation of a leading comprehensive pharmaceutical enterprise.
In addition, Xintian Pharmaceutical said that after the company applied to the Shenzhen Stock Exchange, the company’s shares and convertible corporate bonds resumed trading since the market opened on March 8, and convertible corporate bonds resumed conversion on the same day.
Huibo Yuntong: Plan to increase funding for big data and AI model research and development projects for enterprise application scenarios
() announcement, the proposed increase in funding does not exceed 430 million yuan, for enterprise application scenarios for big data and AI model research and development projects, supplementary working capital.
Huilu Ecology was 575,500 shares by Li Junhao, the son of Li Xiaoming, the actual controller
() Announcement that Li Junhao, the son of Li Xiaoming, the actual controller of the company, increased his holdings of the company’s shares 575,500 shares on March 6, 2024.
Huilu Ecology was 575,500 shares by Li Junhao, the son of Li Xiaoming, the actual controller
Huilu Ecological Announcement, Li Junhao, the son of Li Xiaoming, the actual controller of the company, increased his holdings of the company’s shares 575,500 shares on March 6, 2024.
Jiansheng Green Energy, a subsidiary of Wenke Holdings, plans to build a photovoltaic power station project
() Announcement, the company’s holding subsidiary, Guangdong Jiansheng Green Energy Co., Ltd. (abbreviation: "Jiansheng Green Energy") intends to acquire 100% equity of Huizhou Lingdian New Energy Co., Ltd. (abbreviation: "Project Company"), with the project company as the main body to invest in the construction of rooftop distributed photovoltaic projects, with an estimated total installed capacity of about 7.38MW (subject to the actual installed capacity). The total investment of the project is estimated to be 2625.2 million yuan.
This investment in the construction of a photovoltaic power station project is conducive to enhancing the company’s large-scale business advantages. Together with the company’s other independently developed and operated photovoltaic power stations under construction, the company can expand its coverage in the Pearl River Delta region, enhance the company’s overall competitiveness and product service level, and expand the company’s brand influence.
Xintian Pharmaceutical’s shares resume trading, convertible bonds resume trading and share conversion
Xintian Pharmaceutical announced that the company intends to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 shareholders of Shanghai Huilun Pharmaceutical joint stock company ("Huilun Pharmaceutical"), including Dong Dalun, Dong Zhu and Hainan Qianyao Enterprise Management Partnership (Limited Partnership), by issuing shares ("this transaction"). Upon application, the company’s shares and convertible corporate bonds will be suspended from the opening of the market on February 23, 2024 to March 7, 2024 (Thursday).
During the suspension period, the company signed the "Trading Framework Agreement" with 88 shareholders of Huilun Pharmaceutical, and has formed a preliminary trading intention. Upon application, the company’s shares and convertible corporate bonds will resume trading from the opening of the market on March 8, 2024 (Friday), and convertible corporate bonds will resume conversion on the same day.
Huapengfei and Ririshun Supply Chain Signed a Strategic Cooperation Framework Agreement
Huapengfei announced that in view of the fact that the company and Ririshun Supply Chain Technology joint stock company have their own resources and advantages in the supply chain field, and are committed to commercial cooperation in cross-border integrated logistics and seek common development, the two parties decided to establish a strategic partnership and sign the "Strategic Cooperation Framework Agreement". On the premise of meeting the service experience and cost competitiveness of Ririshun Supply Chain, the company, as the cross-border logistics service team of Ririshun Supply Chain, is entrusted to undertake the cargo transportation tasks of Ririshun Supply Chain, including but not limited to cross-border trucking services, cross-border maritime transportation services, and cross-border railway transportation services. The company provides customized solutions for Ririshun Supply Chain to assist Ririshun Supply Chain in achieving cost reduction and efficiency increase.
Zuoli Pharmaceutical: The company’s exclusive variety Lingze tablets are listed as the national second-level protected variety of traditional Chinese medicine
Zuoli Pharmaceutical announced that recently, the company received the "Certificate of Traditional Chinese Medicine Protected Variety" issued by the State Drug Administration. The company’s exclusive variety Lingze Tablet is listed as the national second-level protected variety of traditional Chinese medicine, and the protection period is from March 1, 2024 to March 1, 2031. Lingze Tablet, as one of the important products of the Wuling series, is an exclusive innovative drug for the treatment of benign prostate hyperplasia and the treatment of symptoms such as frequent nocturnal urination. It is a product of the National Basic Drug Catalog and a Class B product of the National Medical Insurance Catalog.
The 16.7% shares held by Kunlun Investment, the controlling shareholder of Xiangxue Pharmaceutical, were frozen by the judiciary
On the evening of March 7, () issued an announcement saying that recently, the company checked the system of the Shenzhen branch of China Securities Depository and Clearing Co., Ltd., and learned that part of the company’s shares held by the controlling shareholder Guangzhou Kunlun Investment Co., Ltd. (hereinafter referred to as "Kunlun Investment") had been judicially frozen.
The announcement shows that the total number of frozen shares held by Kunlun Investment is about 110 million shares, accounting for 73.91% of its shares and 16.7% of the company’s total share capital. As of the announcement date, Kunlun Investment has frozen about 149 million shares, accounting for 100% of its shares and 22.59% of its total share capital.
Dongfang Seiko: The company does not control Jiateng robots and does not participate in the operation and management of Jiateng robots
Dongfang Seiko announced that the company has recently noticed that some media have listed the company as a "robot + Nvidia" concept stock. Many relevant media reports mention Guangdong Jiateng Robot Automation Co., Ltd. (hereinafter referred to as "Jiateng Robot"), a shareholding company of Dongfang Seiko. The company explains the relevant matters as follows:
(1) Explanation of Dongfang Seiko’s investment in Jiateng Robot. In June 2014, Dongfang Seiko disclosed the "Announcement on Cash Subscription for 20% Equity of Guangdong Jiateng Robot Automation Co., Ltd." The company invested in Jiateng Robot in cash subscription to obtain 20% of its capital contribution, and the transaction consideration was 49.12 million yuan. Since June 2014, Dongfang Seiko has never made additional investment in Jiateng Robot. During this period, due to the introduction of new shareholders and the increase in registered capital of Jiateng Robot, as of now, Dongfang Seiko’s investment in Jiateng Robot is 19.8366%.
(2) Dongfang Seiko’s explanation for not controlling Jiateng Robot and not participating in the operation and management of Jiateng Robot. According to the Company Law and enterprise accounting standards, Dongfang Seiko, as a minority shareholder, does not have the control of Jiateng Robot. Since the initial investment in Jiateng Robot, Dongfang Seiko has never included Jiateng Robot in the scope of consolidated statements, nor has it substantially participated in the operation and management of Jiateng Robot.
(3) The impact of investing in Jiateng Robotics on the financial performance of Dongfang Seiko. Since the initial investment in Jiateng Robotics in June 2014, in the regular reports disclosed every year, Dongfang Seiko has strictly adhered to the relevant provisions of the enterprise accounting standards, recognized Jiateng Robotics as an "associate" for long-term equity investment, and recognized ROI in each reporting period using the equity method. Jiateng Robotics has not paid dividends from 2020 to 2023.
(4) Explanation that Dongfang Seiko and Nvidia do not have a direct cooperative relationship. Dongfang Seiko takes "intelligent equipment manufacturing" as the strategic core, focuses on the direction of high-end intelligent equipment manufacturing, and is mainly engaged in the two fields of "intelligent packaging equipment" and "aquatic power equipment". As of now, Dongfang Seiko has no direct cooperative relationship with Nvidia. Based on Dongfang Seiko’s shareholding ratio for Jiateng Robotics and the accounting treatment of the investment in Dongfang Seiko’s consolidated financial statements, the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term.
Shouhang Hi-Tech signed a procurement contract for the tower concentrating heat collection system of the solar thermal + photovoltaic integrated project
Shouhang Hi-Tech announced that recently, the company (the "seller") and China Energy Construction Group Northwest Electric Power Construction Engineering Co., Ltd. (the "buyer") signed the "Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project tower concentrating heat collection system procurement contract", the contract stipulates that the seller is the buyer Tangshan Haitai New Energy Technology joint stock company solar thermal + photovoltaic integrated project (tower concentrating heat collection system) to provide contract equipment and services, the total contract amount (tax included) 428,718,280.00 yuan.
Liberal Arts Co., Ltd.: Holding subsidiary plans to invest in the construction of photovoltaic power station projects
Wenke shares announced on the evening of March 7 that the holding subsidiary Guangdong Jiansheng Green Energy Co., Ltd. plans to acquire 100% equity of Huizhou Lingdian New Energy Co., Ltd., and invest in the construction of rooftop distributed photovoltaic projects with the project company as the main body. The total installed capacity is expected to be about 7.38MW. The total investment of the project is estimated to be 2625.2 million yuan.
Huibo Yuntong: It is planned to raise no more than 432 million yuan for big data and AI model research and development projects for enterprise application scenarios
Huibo Yuntong announced on the evening of March 7 that it intends to issue shares to specific objects, and the total amount of proceeds raised does not exceed 432 million yuan, which is used for big data and AI large model research and development projects for enterprise application scenarios and supplementary working capital.
Shengxun shares: 244,400 shares were repurchased for the first time
On the evening of March 7, () announced that on March 7, 2024, the company repurchased 244,400 shares of the company through a centralized bidding transaction through a special securities account for share repurchase, accounting for 0.30% of the company’s current total share capital.
Xintian Pharmaceutical plans to acquire 85.12% stake in Huilun Pharmaceutical and resume trading on the 8th
Xintian Pharmaceutical announced that the company plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 Huilun Pharmaceutical shareholders including Dong Dalun, Dong Zhu and Hainan Qianyao by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the company. As of now, the audit and evaluation of the underlying assets of this transaction have not been completed, and the transaction price of the underlying assets of this transaction has not yet been determined. This transaction is expected to constitute a major asset restructuring. Huilun Pharmaceutical’s main business is the research and development, production and sales of small molecule chemical drugs, and is committed to innovative development in the fields of immuno-inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecological, andrology and other diseases. The company said that after the completion of this transaction, the company will further extend its industrial layout to frontier pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine-chemical drugs", and realize the rich integration of product structure, further expansion of the therapeutic field and the upgrade of future innovative drug pipelines. The company’s shares and convertible corporate bonds will resume trading from the opening of the market on March 8, 2024, and convertible corporate bonds will resume conversion on the same day.
Huarong Chemical appointed Zhang Wei as the general manager of the company
() Announcement: On March 7, 2024, the board of directors of the company deliberated and approved the "Proposal on the Appointment and Removal of Senior Managers of the Company". Tang Chong was removed as the general manager and continued to serve in the company. Zhang Wei was appointed as the general manager, and at the same time, Zhang Wei’s deputy general manager, CFO, and board secretary were removed. Cai Xiaoqin was appointed as the CFO and Li Si was appointed as the secretary of the board of directors.
Teyi Pharmaceutical announced the annual rights distribution plan for 2023, and plans to pay 5 yuan for 10 to 4 shares
() announced on March 8 that the company’s 2023 annual equity distribution plan is as follows: based on the total share capital 364.7389 million shares, a cash dividend of RMB 5.00 will be distributed to all shareholders for every 10 shares, a total of RMB 182 million will be distributed, and a capital provident fund will be transferred to all shareholders for every 10 shares.
According to Special Pharmaceutical’s annual performance report for 2023, the company’s operating income was 1.067 billion yuan, an increase of 20.38% year-on-year; net profit attributable to shareholders of listed companies was 253 million yuan, an increase of 42.07% year-on-year; basic earnings per share were 0.77 yuan, 0.57 yuan in the same period last year.
Teyi Pharmaceutical Group joint stock company is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and chemical raw materials. The company’s main products include cough treasure tablets, Ganmaoling granules, compound Houttuynia cordata tablets, pharyngitis tablets, Xuesaitong dispersible tablets, Ginkgo biloba dispersible tablets, Yixinshu granules, aluminum magnesium carbonate chewable tablets, Maple Polygonum Changweikang tablets, omeprazole enteric-coated capsules, roxithromycin capsules, etorubicin tablets, levofloxacin hydrochloride tablets, skin disease blood poison pills, Yikang Beisong cream, children’s cough syrup, children’s Kechuanling granules, Jinkui kidney gas tablets, etc. In addition, 27 medicines including Cough Treasure Tablets, Jinkui Shenqi Tablets, Erythromycin Enteric-coated Tablets and Erythromycin Tablets have been recognized as "Guangdong Province High-tech Products" by the Guangdong Provincial Department of Science and Technology. The company’s special brand has been recognized as "Guangdong Province Famous Trademark" by the Guangdong Provincial Administration for Industry and Commerce, and the special brand has also been rated as "Guangdong Province Leading Brand in the Industry of Proprietary Chinese Medicine and Traditional Chinese Medicine Decoction Pieces" by the Guangdong Provincial Pharmaceutical Industry Association.
(Source: Flush iFinD)
Pengdu agriculture and animal husbandry controlling shareholders acting in concert were judicially frozen 646 million shares
() Announcement, the company recently received a notice from the company’s controlling shareholder, Shanghai Pengxin (Group) Co., Ltd. (referred to as "Pengxin Group"), the concerted action person of Lhasa Economic and Technological Development Zone Houkang Industrial Co., Ltd. (referred to as "Houkang Industrial"), that its holdings of 646 million shares of the company (10.13% of the company’s total share capital) were frozen by the judiciary.
Luoxin Pharmaceutical and Shenzhen Unknown signed a strategic cooperation framework agreement
Luoxin Pharmaceutical announced that the company and Shenzhen Unknown Jun Biotechnology Co., Ltd. signed the "Strategic Cooperation Framework Agreement" on March 7, 2024. Shenzhen Unknown Jun and/or its affiliates will transplant their intestinal flora into medical technology authorized companies and/or their affiliates to exclusively carry out commercialization cooperation within the scope of cooperation areas and channels agreed upon by both parties, including but not limited to distribution, sales, promotion, etc. Both parties agreed to establish a win-win strategic partnership on the basis of complementary advantages, mutual benefit and common development.
Nenghui Technology terminates the implementation of the 2021 restricted stock incentive plan
() Announcement, the board of directors and the board of supervisors of the company deliberated and approved the "Proposal on Terminating the Implementation of the 2021 Restricted Stock Incentive Plan and Repurchase, Cancellation and Voiding of Restricted Shares", and intends to decide to terminate the implementation of the incentive plan, and to repurchase and cancel all the first-class restricted stocks that have been granted but not yet lifted and all the second-class restricted stocks that have been granted but not yet vested, and the relevant supporting documents shall be terminated together.
Lianke Technology announced the 2023 annual rights distribution plan, proposing to pay 5 yuan out of 10
() announced on March 8 that the company’s 2023 annual equity distribution plan is as follows: Based on the total share capital 202.356 million shares, cash dividends of RMB 5.00 will be distributed to all shareholders for every 10 shares, and a total cash dividend of RMB 101 million will be distributed. No bonus shares will be sent, and no capital reserve will be converted into equity.
According to the 2023 annual performance report released by Lianke Technology, the company’s operating income was 1.917 billion yuan, an increase of 4.45% year-on-year; net profit attributable to shareholders of listed companies was 169 million yuan, an increase of 51.27% year-on-year; basic earnings per share were 0.88 yuan, 0.61 yuan in the same period last year.
Shandong Lianke Technology joint stock company is a high-tech enterprise specializing in the research and development, production and sales of silica and carbon black. The silica products mainly include LK, LKHD and LKSIL series rubber industrial silica and non-rubber industrial silica; carbon black products mainly include N100, N200, N300, N400, N500, N600, N700 series and LK series rubber carbon black and special carbon black. The company’s silica and carbon black products have been certified by Pirelli Tire, Yokohama, Zhengxin Rubber, Cooper Tire, () and (), (), Aeolus Tire, Shuangxing Tire, Pulin Chengshan and other well-known tire and footwear companies in the world-renowned tire companies.
(Source: Flush iFinD)
Huarong Chemical announced the 2023 annual rights and interests distribution plan, proposing to send 2 yuan to 10
Huarong Chemical announced on March 8 that the company’s 2023 annual equity distribution plan is as follows: Based on the total share capital 480 million shares, cash dividends of RMB 2.00 will be distributed to all shareholders for every 10 shares, and a total of RMB 96 million will be distributed. No bonus shares will be sent, and no capital reserve will be converted into equity.
According to Huarong Chemical’s annual performance report for 2023, the company’s operating income was 1.059 billion yuan, down 6.67% year-on-year; net profit attributable to shareholders of listed companies was 139 million yuan, an increase of 13.53% year-on-year; basic earnings per share were 0.29 yuan, 0.27 yuan in the same period last year.
Huarong Chemical joint stock company is an advanced enterprise dedicated to the green recycling and comprehensive utilization of potassium hydroxide. The main products are high-quality potassium hydroxide. The company focuses on the development of electronic-grade, photovoltaic-grade, reagent-grade, food-grade fine potassium products and chlorine products around modern industries such as new fertilizers, high-end daily chemicals, food and medicine, new energy, and electronic information. The company has won the titles and awards of "National Advanced Collective of Petroleum and Chemical Industry", "Third Class of Science and Technology Progress Award", "Sichuan Province Oil and Gas Chemical Industry" Twelfth Five-Year "Development Advanced Unit", "Sichuan Famous Brand Product Title", "Sichuan Province Famous Trademark" and other titles and awards.
(Source: Flush iFinD)
Jujie Microfiber: The controlling shareholder plans to increase the company’s shares by 1,500 to 30 million yuan
China Fortune Connect, March 7 – Jujie Microfiber announced that based on confidence in the company’s future development and recognition of long-term investment value, the company’s controlling shareholder Suzhou Jujie Investment Co., Ltd. plans to increase its holdings of the company’s shares within the next 6 months from the date of this announcement through the means allowed by the China Securities Supervision Commission and the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block trading, etc.), with a total proposed increase of not less than 15 million yuan and not more than 30 million yuan.
Xintian Pharmaceutical plans to purchase part of the equity of Huilun Pharmaceutical and resume trading on March 8
Xintian Pharmaceutical announced on the evening of March 7 that it plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 Huilun Pharmaceutical shareholders including Dong Dalun, Dong Zhu and Hainan Qianyao by issuing shares. After the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company. This transaction does not involve raising supporting funds. At the same time, Xintian Pharmaceutical’s shares and convertible corporate bonds have resumed trading since the opening of the market on March 8, and convertible corporate bonds have resumed conversion on the same day.
Focus on small molecule chemicals
Before this transaction, Xintian Pharmaceutical’s main business was the research and development, production and sales of proprietary Chinese medicines. The product indications were mainly for gynecological and urinary diseases, and covered oral, mammary and thyroid, anti-cold, heat-clearing, blood supplementation, cardiovascular diseases, anti-tumor and other disease fields.
In the field of traditional Chinese medicine, Xintian Pharmaceutical has 32 drug production batches, including 10 national medical insurance catalog varieties, 1 national essential drug catalog variety, 12 over-the-counter (OTC) varieties, and 12 exclusive varieties. The main product pipeline market such as gynecology and urinary system, and many main varieties have achieved a sales scale of over 100 million single products. Among them, Xintian Pharmaceutical has a leading clinical market position and industry position in the gynecological field.
After years of traditional Chinese medicine industry marketing network construction and market mining, the current product market has covered more than 30 provinces, autonomous regions and municipalities across the country, prescription drug products cover more than 12,000 hospitals above the county (district) level; OTC products cover more than 800 drug chain companies, nearly 100,000 stores, and established long-term and stable business relationships with the headquarters of nearly 500 domestic drug chain companies.
The main business of the target company, Huilun Pharmaceutical, is the research and development, production and sales of small molecule chemical drugs, and is committed to innovation and development in the fields of immuno-inflammation, anti-tumor, cardiovascular and cerebrovascular, gynecological, andrology and other diseases. After years of technical accumulation and business development, Huilun Pharmaceutical has approved a number of chemical drugs for listing. As of the signing date of the plan, Huilun Pharmaceutical has approved 12 varieties for listing, including 1 new improved drug and 3 first imitation drugs. The drug treatment fields cover immuno-inflammation, anti-tumor, gynecology, andrology, cardiovascular and cerebrovascular systems, etc.
Huilun Pharmaceutical’s exclusive product, Silvestrat Sodium for Injection, is mainly used to improve acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) accompanied by systemic inflammatory response syndrome. The product has obtained the qualification of accelerated review by the State Food and Drug Administration, and has obtained clinical approval through emergency review. It is also the first drug approved in China for the treatment of ALI and ARDS.
In terms of performance, from 2022 to 2023, Huilun Pharmaceutical achieved revenue of 414 million yuan and 998 million yuan, and net profit was – 264 million yuan and 30.8325 million yuan.
Constitutes a material asset reorganization
According to the transaction plan, Xintian Pharmaceutical plans to purchase 85.12% of the equity of Huilun Pharmaceutical held by 88 Huilun Pharmaceutical shareholders including Dong Dalun, Dong Zhu and Hainan Qianyao by issuing shares. This transaction does not involve raising supporting funds. As of the signing date of the plan, Xintian Pharmaceutical has held 14.88% of the equity of Huilun Pharmaceutical; after the completion of this transaction, Huilun Pharmaceutical will become a wholly-owned subsidiary of the listed company.
The price of the shares issued this time is 8.12 yuan/share. As of the signing date of the plan, the audit and evaluation of the underlying assets of this transaction have not been completed, and the transaction price has not yet been determined. Judging from the unaudited financial data of the target company in 2023, this transaction is expected to constitute a major asset restructuring, but it will not lead to a change in the actual controller of the company.
In addition, Dong Dalun, Dong Zhu, Hainan Qianyao, LIUZHENWANG, Huilun Yuyi, Huilun Feihe, Huilun Yunbai, Tianxiang Shengtai, Wang Jinhua, Wang Guangping, Wang Wenyi, Chen Yurong, Ji Weijia, Dong Dahua, Dong Daheng, and Yuan Ye are related parties of Xintian Pharmaceutical, and this transaction constitutes a related party transaction.
Xintian Pharmaceutical said that after the completion of this transaction, the listed company will further enrich the product pipeline in the company’s specialty field, improve the product matrix, and provide patients with more comprehensive medication options, thereby improving the market coverage and influence of the listed company in the main drug field. At the same time, Xintian Pharmaceutical will integrate the marketing activities of both parties, deeply integrate in the fields of gynecology, andrology and other diseases, improve the efficiency of drug marketing activities in the same department, enrich the choice space of doctors, and simultaneously increase the layout of sales channels such as OTC and e-commerce, as well as sales coverage areas and coordinated development.
At the same time, Xintian Pharmaceutical will further extend its industrial layout to cutting-edge pharmaceutical fields such as small molecule chemical drugs, forming a dual-category industrial pattern of "traditional Chinese medicine – chemical drugs", realizing rich integration of product structure, further expansion of treatment field and upgrading of future innovative drug pipelines, superimposing the synergy effect of clinical medical research and marketing activities with the products of the target company, further enhancing the clinical marketing capabilities of the company’s core products and the market competitiveness of product pipelines, accelerating the creation of a leading comprehensive pharmaceutical enterprise, and enhancing Xintian Pharmaceutical’s competitiveness in the pharmaceutical industry.
Zhongbing Hongjian: Completion acceptance of some investment projects with proceeds raised
() Announcement, the company’s wholly-owned subsidiary Shandong North Binhai Machinery Co., Ltd. (referred to as North Binhai) has completed all the construction content of the approval, and the acceptance team composed of relevant departments and experts has completed the on-site completion acceptance. The environmental protection, fire protection, safety facilities, occupational health, construction and safety engineering quality and project files of the project have passed the special project acceptance organized by the local competent department or construction unit according to the regulations and requirements in the early stage. Recently, the project received the approval of the relevant departments through the completion acceptance.
Copyright Daily Economic News
Three special ropeway: the company received a first instance court verdict involving 72.9764 million yuan
() Announcement, recently, the company received the "Civil court verdict" of the People’s Court of Wuhan East Lake New Technology Development Zone, Hubei Province ([2023] Hubei 0192 Minchu No. 3153). The subject matter of the lawsuit is 72.9764 million yuan. The first-instance judgment result: The defendant, Wuhan Sante Cableway Group Joint Stock Company, within 60 days from the effective date of the judgment, registered the change of the land use right under the WP National Use (2000) No. 150 and WP National Use (2000) No. 151 "State-owned Land Use Certificate" to the name of the third party, Wuhan Hanjintang Investment Co., Ltd.; rejected the other claims of the plaintiff, Hubei Heyuesheng Investment Co., Ltd.
Zuoli Pharmaceutical: Lingze Tablets Received the "Certificate of Protected Varieties of Traditional Chinese Medicine"
On March 7, Zuoli Pharmaceutical announced that Lingze tablets received the "Certificate of Protected Varieties of Traditional Chinese Medicine".
Copyright Daily Economic News
Continue to increase shareholder returns, Jianfan Bio promotes the implementation of the "Double Improvement of Quality Returns" action plan
() An announcement on promoting the implementation of the "Double Improvement of Quality and Return" action plan was issued after the market close on March 7. In terms of operation, the company focuses on the main business of blood purification, increases investment in research and development, launches series of blood purification products, and builds a world-class high-tech medical technology enterprise group. In terms of returning shareholders, it actively distributes dividends and shares development results with shareholders, and enhances investor confidence through repurchase, increase holdings, etc.
Data show that since its listing in 2016, the company has implemented a cash dividend plan for seven consecutive years, with a cumulative cash dividend of 2.642 billion yuan, which is 6.35 times the company’s net IPO raising of 416 million yuan and 1.87 times the company’s net financing (IPO and refinancing) since its listing. The proportion of the company’s cash dividends to net profit has increased from 41% in 2016 to 60% in 2022. The company also shares the company’s development results with investors through various forms of dividends such as "transfer of equity" and "share repurchase". In the future, the company will, in accordance with the relevant provisions of the Articles of Association and the Shareholder Dividend Return Plan for the Next Three Years (2023-2025), take into account the Strategy and Development Plan and Shareholder Return, and continue to increase the return to shareholders under the premise of ensuring the company’s business expansion, so as to create greater value for shareholders.
In the secondary market, the company carried out share increase and repurchase to actively maintain market stability and enhance investor confidence. Dong Fan, the controlling shareholder and actual controller, chairperson and general manager of the company, increased his holdings by a total of 200 million yuan through centralized bidding transactions from January 20, 2022 to March 11, 2022. The company implemented two phases of the share repurchase plan of the company. The first phase of the share repurchase plan completed on November 12, 2021 had a total transaction amount of 500 million yuan, and the number of shares repurchased 8.8478 million shares, accounting for 1.10% of the company’s total share capital at that time. On July 17, 2023, the company launched the share repurchase plan of the company for the second time, using equity funds to repurchase the company’s shares in a centralized bidding mode of not less than 250 million yuan and not more than 500 million yuan. As of February 28, 2024, the company has repurchased 17.5827 million shares, accounting for 2.18% of the company’s total share capital, and the repurchase amount is 342 million yuan, which will continue to be implemented. So far, the company’s two-phase share repurchase plan has repurchased the company’s shares for a total of 842 million yuan, and the cumulative number of repurchased shares 2643.05 million, accounting for 3.27% of the company’s total share capital. The company has actively launched the share repurchase plan to effectively maintain market stability and boost investor confidence.
Feneng Oriental: It plans to apply for a comprehensive exposure credit line of not more than 2.43 billion yuan to the Financial Institution Group within the next year
China Fortune Connect, March 7 – () announcement said that according to the needs of production and operation, in order to reduce financing costs and improve the efficiency of capital use, the company (including wholly-owned and holding subsidiaries) plans to apply to banks, financial leasing companies and other Financial Institution Groups within the next year for a total amount of not more than RMB2.43 million in comprehensive exposure credit lines and handle corresponding loans, financial leasing, factoring and other businesses.
Rifeng shares: In order to ensure the smooth construction and implementation of related projects, it plans to apply for a project loan from the bank with its own assets as collateral
China Fortune Connect, March 7 – Rifeng announced that in order to ensure the smooth construction and implementation of the company’s "new energy and special equipment cable assembly project", the company plans to mortgage the state-owned construction land and its under-construction projects in Longchang Community, West District, Zhongshan City, Guangdong Province to the Zhongshan Branch of the Bank of Communications joint stock company, and add no more than 150 million yuan (exposure 150 million yuan) of bank credit and apply for project loans. The specific loan amount and term are subject to the final agreement signed with the bank. The company’s application for project loans from the bank with its own assets as collateral is to meet the capital needs of the company’s under-construction projects, which is conducive to the long-term sustainable development of the company.
Funeng Oriental: plans to cancel its subsidiary Zhongshan Daewoo, which will help the company improve the efficiency of asset operation
China Fortune Connect, March 7 – Funeng Oriental announced that the company intends to cancel its wholly-owned subsidiary Zhongshan Daewoo Intelligent Equipment Co., Ltd. This cancellation is conducive to the company’s further integration of resources, improvement of asset operation efficiency, and reduction of management costs. After the cancellation is completed, Zhongshan Daewoo will no longer be included in the company’s consolidated financial statements, which will not have a material impact on the company’s consolidated financial statements, nor will it have an adverse impact on the company’s overall business development and profitability.
Double in 10 days! Big bull stocks urgently clarify
On the evening of March 7, Dongfang Seiko, a bull stock with 8 daily trading limits in 10 days, issued an announcement of abnormal fluctuations in stock trading for the third time.
This time, the company disclosed in detail the investment in Jiateng Robotics, whose current shareholding ratio is close to 20%. The company said that the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term, while continuing to emphasize that "there is no direct partnership with Nvidia".
From the perspective of the transaction returns after the daily limit on March 7, the game of hot money in Dongfang Seiko is in full swing. There are many well-known hot money seats in the top five of buying and selling, and the net transaction is relatively close.
Holding Jiateng Robot 19.84%
On March 7, Dongfang Seiko rose by the daily limit again. In this way, the company’s closing price rose by a cumulative 20% for 3 consecutive trading days. According to the relevant regulations of the Shenzhen Stock Exchange, this situation belongs to the abnormal fluctuation of stock trading. Since February 23, the company has harvested 8 daily limit in 10 days, and the cumulative increase in stock price has reached 100%.
On the evening of March 7, the company released its third announcement of abnormal stock price fluctuations since the current round of gains.
The announcement said that the company has recently noticed that some media have listed the company as a "robot + NVIDIA" concept stock, and many relevant media reports have mentioned Guangdong Jiateng Robot Automation Co., Ltd. (referred to as "Jiateng Robot").
The announcement shows that in June 2014, Dongfang Seiko invested in Jiateng Robot in cash subscription to obtain 20% of its investment ratio, and the transaction consideration was 49.12 million yuan. Since June 2014, Dongfang Seiko has never made additional investment in Jiateng Robot. During this period, due to the introduction of new shareholders and the increase in registered capital of Jiateng Robot, as of now, Dongfang Seiko’s investment ratio in Jiateng Robot is 19.8366%.
The company said that since the initial investment in Jiateng Robot, Dongfang Seiko has never included Jiateng Robot in the scope of consolidated statements, nor has it substantially participated in the operation and management of Jiateng Robot. The company adopts the equity method to confirm the ROI of the investment in each reporting period, and the confirmed ROI in the past three years is 3.06 million yuan, 3.88 million yuan, 3.14 million yuan and – 1.78 million yuan respectively.
The announcement said that as of now, Dongfang Seiko has no direct cooperation relationship with Nvidia. Based on Dongfang Seiko’s shareholding ratio for Jiateng Robot and the accounting treatment of the investment in Dongfang Seiko’s consolidated financial statements, the application of robots or AI-related technologies will not have a significant impact on the company’s operating results in the short term.
Jiateng robot repeatedly sends "good"
Although Dongfang Seiko has tried its best to downplay the influence of Jiateng Robotics and Nvidia, it has repeatedly released "good news" on official Weibo and other channels, and has been noticed by the market.
According to its official website, Jiateng Robotics is a global enterprise headquartered in Shunde, China. It was established in 2002 and focuses on the research and development and manufacturing of mobile robot (AGV) bodies. It is the world’s leading provider of AGV robots and intelligent logistics warehousing systems. "Committed to promoting the transformation and upgrading of the manufacturing industry and the development of new quality productivity, to be the best AGV to help people around the world carry and run errands."
On January 9, Jiateng Robot released a message on the official Weibo, based on years of long-term cooperation and deep consensus in the intelligent application field, NVIDIA, the global artificial intelligence leader, highly recognized Jiateng’s leading generative AI, and presented the application in a multi-scene and multi-modal display at the CES exhibition in the United States where intelligent innovation projects are gathered. In particular, the successful application of Jiateng’s generative AI on laser forklifts has depicted a vivid and magnificent vision for the promotion and popularization of thinking mobile robots in the industry, and has become a typical example of NVIDIA’s global artificial intelligence players at CES.
On February 28, Jiateng Robot’s official Weibo account was again favorable, claiming that its Jiateng 8.5 cm ultra-thin fork arm omnidirectional unmanned stacking forklift conference was held in the studio of Guangdong Jiateng Robot Headquarters.
From the dragon and tiger list on March 7, the short-term game of capital in Oriental Seiko does not seem to have ended. There are still many well-known hot money seats in the top five of buying and selling, including CITIC Securities Xi’an Suzaku Street Sales Department, East Asia Qianhai Securities Shenzhen Branch, etc. In addition, Shenzhen Stock Connect seats also participated.
BYD applies for a patent for a hydraulic control system to prevent the load from shaking
According to the announcement of the State Intellectual Property Office, the joint stock company applied for a project entitled "Hydraulic control system and its control method, and vehicle", public number CN117658019A, and the application date is August 2022.
The patent abstract shows that the present invention provides a hydraulic control system and a control method thereof, as well as a vehicle. The hydraulic control system includes an oil pump, a first oil cylinder connected to the oil pump, and a motor for driving the oil pump to supply oil to the first oil cylinder. The telescopic rod of the first oil cylinder is connected to the first load member. The hydraulic control system also includes a controller connected to the motor and a buffer switch connected to the controller. The controller is used to control the motor. The buffer switch is used to drive the first load member in the telescopic rod of the first oil cylinder. When moving in the extended direction to a preset stroke, a buffer signal is generated and sent to the controller; the controller controls the motor to reduce from the first speed to the second speed based on the buffer signal, so that the speed at which the telescopic rod of the first oil cylinder drives the first load member to move is reduced from the In the present invention, the controller controls the motor speed to decrease or even stop slowly based on the buffer signal, which can eliminate the impact caused by inertia when the first cylinder mechanically travels to the end, and prevent the first load member from shaking.
BYD applies for patents related to sodium-ion batteries to provide over-discharge protection
According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project entitled "A sodium-ion battery positive electrode piece, sodium-ion battery and application", public number CN117673243A, and the application date is August 2022.
The patent abstract shows that this application provides a sodium-ion battery positive electrode sheet, a sodium-ion battery, and applications. The sodium-ion battery positive electrode sheet includes an active material and an over-discharge protector, including an over-discharge protector of the chemical formula M.
BYD applies for patents for anti-skid devices and rail vehicles to reduce wear on running wheels
According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for a project called "anti-skid device and rail vehicle", public number CN117657223A, and the application date is August 2022.
The patent abstract shows that the present application discloses an anti-skid device and a rail vehicle. The rail vehicle is used to travel on a metal rail beam, and the anti-skid device includes a skid monitoring unit and an electromagnetic coil; the skid monitoring unit is used to monitor the skid of the rail vehicle; the electromagnetic coil is arranged facing the metal rail beam and is electrically connected to the skid monitoring unit. When the skid monitoring unit detects the skid of the rail vehicle, the voltage or current of the electromagnetic coil is increased, so that the magnetic force of the electromagnetic coil on the metal rail beam is increased. Therefore, during the running of the rail vehicle, the skid monitoring unit can monitor in real time whether the running wheels of the rail vehicle are slipping. When the skid monitoring unit detects the skid of the rail vehicle, the voltage or current of the electromagnetic coil is controlled to increase. In this way, the friction between the running wheels and the metal track beam can be increased to reduce the degree of skidding of the running wheels on the metal track beam, thereby reducing the wear of the running wheels.
BYD applies for optical structure, end point shell and end point patent, patented technology can make pattern formation have three-dimensional effect
According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for a project called "optical structure, end point shell and end point", public number CN117677087A, and the application date is August 2022.
The patent abstract shows that this application provides an optical structure, an end point housing, and an end point. The optical structure includes a substrate layer, a pattern layer, and a microlens layer. The substrate layer includes opposing first and second surfaces. The pattern layer is arranged on the first surface of the substrate layer. The pattern layer includes a plurality of pattern units arranged in an array, and each pattern unit is part of a preset pattern. The microlens layer is arranged on the second surface of the substrate layer. The microlens layer includes a plurality of microlenses arranged in an array. Each microlens corresponds to a pattern unit, and each pattern unit is located within the projection of the corresponding microlens on the pattern layer. Wherein, the plurality of microlenses are used to cause the plurality of pattern units to form a preset pattern with a stereoscopic effect. The present application provides an optical structure, the end point of the housing and the end point, by each pattern unit in the pattern layer is provided as part of a predetermined pattern, so that a predetermined pattern having a stereoscopic effect can be formed by a plurality of microlenses.
BYD applies for a battery preparation system patent to improve battery preparation efficiency
According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project entitled "Cell Preparation System, Cell Preparation Method, Laminated Cell and Battery", public number CN117673427A, and the application date is August 2022.
The patent abstract shows that the present invention provides a battery cell preparation system, a battery cell preparation method, a laminated battery cell and a battery. The battery cell preparation system includes a handling mechanism, a positioning member, a roller set for transporting the diaphragm, and a laminating stage disposed below the roller set. The diaphragm is partially laid on the laminating stage, and the diaphragm can be folded when the laminating stage is switched between the first laminating position and the second laminating position. The handling mechanism is used for transporting the first pole piece to the diaphragm above the laminating stage laminated in the first laminating position, and for transporting the second pole piece to the diaphragm above the laminating stage laminated in the second laminating position. The positioning member can be moved between the first auxiliary position and the second auxiliary position, and the positioning members located in either auxiliary position are bonded to the surface of the diaphragm facing away from the lamination stage from one side of the diaphragm in the width direction to the other side. It is used to fix the lamination stage relative to the lamination stage to support the diaphragm during the lamination position switching process of the lamination stage, and move to the corresponding auxiliary position when the lamination stage completes the lamination position switching and the diaphragm is laminated with a first pole piece or a second pole piece.
BYD applied for a patent for the control method, system, storage medium and target controller of the logic section, which increased the flexibility of manual path selection and greatly improved the dispatching efficiency
According to the announcement of the State Intellectual Property Office, BYD joint stock company applied for a "control method, system, storage medium and target controller of logical section", public number CN117657259A, and the application date is August 2022.
The patent abstract shows that the present disclosure relates to a control method, system, storage medium and target controller of a logical section. By acquiring a section control instruction triggered by a dispatcher through the automatic vehicle monitoring system ATS, the section control instruction includes the dispatcher. The ATS selects a target logical section from a plurality of preset logical sections, and the section control instruction is used to instruct the corresponding section path of the target logical section as an artificial path, or to instruct to cancel the section path as the artificial path. According to the section control instruction, section control is performed on the target logical section; the method can use the selected logical section as an artificial path, and no longer rely on the position of the signal to determine the manual path. In this way, the flexibility of manual path selection is increased, and the scheduling efficiency is greatly improved.
BYD applies for a patent for bogies and rail vehicles, which can enhance the riding experience for those located inside the vehicle
According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project called "Bogies and Rail Vehicles", public number CN117657234A, and the application date is August 2022.
The patent abstract shows that this application discloses a bogie and a rail vehicle. The bogie includes a shaft bridge, a first elastic member, a second elastic member, a first support frame and a second support frame; the lower ends of the two elastic members are connected to the shaft bridge; the first support frame is used to fix the vehicle body connected to the rail vehicle; the second support frame is connected to the upper ends of the two elastic members, and the second support frame is rotatably connected to the first support frame. Thereby, the first support frame is used for connecting to the vehicle body, the second support frame is connected to the upper ends of the two elastic members, the lower ends of the two elastic members are connected to the shaft bridge, and the first support frame is rotatably connected to the second support frame. In this way, when the rail vehicle provided with the bogie travels in the extending direction of the track beam, if there is a difference in the height position of the two running surfaces of the track beam, the vehicle body swings about the rotation axis of the first support frame and the second support frame, and the vehicle body swings with less freedom, which can improve the riding experience of the person located in the vehicle body.
BYD applies for an information processing patent to achieve the effect of non-sensory parking for vehicles
According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for an application entitled "Information Processing Method, Server, Parking Method, Parking System and Vehicle", public number CN117671989A, and the application date is August 2022.
The patent abstract shows that the present application relates to an information processing method, which is applied to a server, comprising: acquiring parking information of a plurality of vehicles, wherein the parking information of each vehicle includes the vehicle position and the vehicle attitude of the vehicle parking; determining the parking position and the direction of the parking space based on the parking information; determining the usable parking space based on the parking position and the direction of the parking space; obtaining a parking space map including the usable parking space according to the available parking space. Through the information processing method applied to the server by the present application, it is possible to expand the search range of the parking space, and recommend a parking space with a high confidence level for the vehicle, thereby realizing the non-sensory parking effect of the vehicle. The present application also provides a vehicle, an information processing method applied to the vehicle, a parking system and a parking method applied to the parking system.
BYD patented identification method for display devices to improve system start-up efficiency
According to the announcement of the State Intellectual Property Office, the BYD joint stock company applied for a "identification method, device, medium, display system and vehicle of display equipment", public number CN117676157A, and the application date is August 2022.
The patent abstract shows that the present disclosure relates to an identification method, device, medium, display system and vehicle of a display device to improve system start-up efficiency. Applied to a controller, the controller is connected to at least one display device, and each said display device is provided with a memory for storing a device code of the display device; the method comprises: establishing a communication connection with a target display device to be identified, and the target display device is one of the at least one display device; after the communication connection is successfully established, access the memory of the target display device through the target memory address to read the device code stored in the memory; determine the model of the target display device based on the read device code.
BYD applies for a patent for rotary components to improve the safety and service life of rotary components
According to the announcement of the State Intellectual Property Office, BYD’s joint stock company applied for a project entitled "Rotary components and motor components, electric assemblies and vehicles with them", public number CN117672662A, and the application date is August 2022.
The patent summary shows that the present invention discloses a swirl assembly and a motor assembly, an electric motor assembly and a vehicle having the same, the swirl assembly comprising: a primary housing, the primary housing is provided with a primary winding; a secondary housing, one end surface of the secondary housing in the axial direction is directly opposite the primary housing, a secondary winding is provided in the secondary housing, and the secondary housing is facing away from the primary housing. A first annular wall is formed on the other end surface, and a balance hole is formed inside or on the surface of the first annular wall. The swirling component of the present invention fully considers the dynamic balance problem during the high-speed rotation of the secondary winding during the design process, and the balance hole on the secondary side casing can reduce the weight of the secondary side casing, so as to maintain the quality distribution of the secondary side casing. Uniformity, reduce the failure rate of the swirling component, and improve the safety and service life of the swirling component.
() Apply for a patent for monodisperse magnetic nanoparticles and their preparation method, and prepare magnetic nanoparticles with basically the same morphology and controllable particle size
According to the announcement of the State Intellectual Property Office, Guangzhou Da’an Gene joint stock company applied for a project called "a monodisperse magnetic nanoparticle and its preparation method", public number CN117658224A, and the application date is August 2022.
The patent abstract shows that the embodiment of the present application belongs to the technical field of magnetic nanomaterials, and relates to a monodisperse magnetic nanoparticle and a preparation method thereof, including adding a weakly basic salt and polyethylene glycol to ethylene glycol, mixing uniformly to obtain A liquid; dissolving a soluble iron salt in ethylene glycol to obtain B liquid; mixing A liquid and B liquid and performing ultrasonic operation to obtain a precursor liquid; heating the precursor liquid, cooling the reaction product to room temperature, pouring out the supernatant to obtain the reaction product; washing and drying the reaction product to obtain the magnetic nanoparticle. The present application can achieve the purpose of regulating the particle size of the product, and preparing the magnetic nanoparticle with a substantially uniform morphology and controllable particle size. At the same time, the preparation method is simple and reliable, and mass production can be achieved.
() Apply for a patent for a four-way valve and air conditioning equipment to solve the problem of refrigerant backflow in the refrigerant system, thereby improving the lifespan of the refrigerant circulation system
According to the announcement of the State Intellectual Property Office, Zhejiang Dunan artificial environment joint stock company applied for a project called "four-way valve and air conditioning equipment", public number CN117662804A, and the application date is August 2022.
The patent abstract shows that the present application relates to the technical field of heat exchange, in particular to a four-way valve and air conditioning equipment. In particular, the four-way valve provided by the present application includes a first nozzle and a main valve body. The first nozzle is used to connect the exhaust port of the compressor. The main valve body is provided with a valve cavity, and the first nozzle is connected to the main valve body and connected to the valve cavity. The valve cavity is provided with a flow blocking structure. When the refrigerant flows from the first nozzle to the valve cavity, the refrigerant can push the flow blocking structure to move in a direction away from the first nozzle so that the first nozzle communicates with the valve cavity. When the refrigerant has a tendency to flow from the valve cavity to the first nozzle, the refrigerant can push the flow blocking structure to move in a direction close to the first nozzle to cut off the first nozzle and the valve The four-way valve provided herein solves the problem of refrigerant backflow in a refrigerant system, thereby increasing the life of the refrigerant circulation system.
TCL Technology applies for a patent for the preparation method of side electrodes, which is conducive to the development of narrow-bezel or even bezel-less panels
According to the announcement of the State Intellectual Property Office, the () group joint stock company applied for a project entitled "Side electrode preparation method, substrate with side electrode, electrode and display panel", public number CN117672963A, and the application date is August 2022.
The patent abstract shows that the present application discloses a method for preparing side electrodes, a substrate with side electrodes, electrodes, and a display panel. The side surface of the first substrate of the present application includes a transition surface, and the side surface is connected to the first surface through the transition surface. The transition surface includes at least one of a plane and a curved surface. In this way, the side electrode can be effectively prevented from falling off, and an adhesive layer is provided between the first substrate and the side electrode, which can improve the adhesion of the side electrode process, improve the yield, and facilitate the development of narrow-bezel or even bezel-free panels.
BYD Semiconductor applies for an overcurrent protection circuit patent, which can avoid frequent circuit disconnection affecting the use of power devices
According to the announcement of the State Intellectual Property Office, BYD Semiconductor joint stock company applied for an application entitled "An overcurrent protection circuit and a control method based on overcurrent protection circuit", public number CN117674788A, and the application date is August 2022.
The patent abstract shows that the present invention provides an overcurrent protection circuit and a control method based on the overcurrent protection circuit. The overcurrent protection circuit includes a comparator and a signal modifier, and the output end of the comparator is connected to the input end of the signal modifier; the input end of the comparator is connected to the current output end of the switching component in the power device; and the output end of the signal modifier is connected to the switching control end of the switching component. Through the embodiment of the present invention, the overcurrent protection of the power device is realized by modifying the control signal of the switching component, without completely disconnecting the circuit and then manually resetting, avoiding frequent disconnection of the circuit affecting the use of the power device, and enabling All cases where the current is too large are treated with overcurrent protection, which avoids damage to the power device due to the absence of overcurrent protection treatment due to the presence of some cases where the current is too large.
